

Consolidated Financial Statements

June 30, 2017 and 2016

(With Independent Auditors' Report Thereon)

# **Table of Contents**

	Page
Independent Auditors' Report	1
Consolidated Financial Statements:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Unrestricted Net Assets	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7
Supplemental Schedule	
Consolidating Balance Sheet Information	48
Consolidating Statement of Operations and Changes in Unrestricted Net Assets Information	49
Consolidating Statement of Changes in Net Assets Information	50



KPMG LLP Aon Center Suite 5500 200 E. Randolph Street Chicago, IL 60601-6436

## **Independent Auditors' Report**

The Board of Trustees
The University of Chicago Medical Center:

## **Report on the Financial Statements**

We have audited the accompanying consolidated financial statements of The University of Chicago Medical Center, which comprise the consolidated balance sheets as of June 30, 2017 and 2016, and the related consolidated statements of operations and changes in unrestricted net assets, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

## Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

## Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The University of Chicago Medical Center as of June 30, 2017 and 2016, and the results of its operations and of its cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.



## Other Matter

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The 2017 supplementary information included in schedules 1 through 3 is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.



Chicago, Illinois October 27, 2017

# Consolidated Balance Sheets

# June 30, 2017 and 2016

(In thousands)

Assets	201	17	2016
Current assets:			
<u>.</u>	\$ 3	37,446	20,335
Patient accounts receivable, net of estimated uncollectibles of \$140,878	40	20.400	200 404
in 2017 and \$73,746 in 2016 Current portion of investments limited to use		32,100 20,608	288,401 36,768
Current portion of investments inflited to use  Current portion of malpractice self-insurance receivable		21,141	18,289
Current portion of pledges receivable		1,256	1,661
Prepaids, inventory, and other current assets	8	35,921	62,614
Total current assets	59	98,472	428,068
Investments limited to use, less current portion	1,20	2,972	894,808
Property, plant, and equipment, net	1,62	25,205	1,380,132
Pledges receivable, less current portion		2,363	2,489
Malpractice self-insurance receivable, less current portion		99,798	99,121
Other assets, net		88,654	14,827
Total assets	\$3,56	67,464	2,819,445
Liabilities and Net Assets			
Current liabilities:			
• • •	-	22,595	166,173
Current portion of long-term debt	1	9,418	13,255
Current portion of other long-term liabilities	4-	198	
Estimated third-party payor settlements Current portion of malpractice self-insurance liability		78,181	139,429
Due to University of Chicago		21,141 28,725	18,289 22,146
·			
Total current liabilities	47	70,258	359,292
Other liabilities:		F 000	0.005
Workers' compensation self-insurance liabilities, less current portion Malpractice self-insurance liability, less current portion	19	5,980 31,535	6,305 99,121
Long-term debt, less current portion		4,827	843,039
Interest rate swap liability		29,450	165,417
Other long-term liabilities, less current portion		14,469	30,618
Total liabilities	1,79	96,519	1,503,792
Net assets:			
Unrestricted	1,66	3,039	1,225,616
Temporarily restricted	9	0,461	81,925
Permanently restricted	1	7,445	8,112
Total net assets	1,77	70,945	1,315,653
Total liabilities and net assets	\$ 3,56	67,464	2,819,445

# Consolidated Statements of Operations and Changes in Unrestricted Net Assets

# Years ended June 30, 2017 and 2016

(In thousands)

Operating revenues:         S         2,009,559         1,574,252           Provision for doubtful accounts         152,888         84,243           Net patient service revenue after provision for doubtful accounts         1,856,671         1,490,009           Other operating revenues and net assets released from restrictions used for operating purposes         148,790         126,625           Total operating revenues         2,005,461         1,616,634           Operating expenses:         859,641         698,752           Salaries, wages, and benefits         859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,224           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         82,375         106,439           Nonoperating gains and losses:         1,510,195           Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Change in fair value of nonhed		_	2017	2016
Net patient service revenue	Operating revenues:		_	
Provision for doubtful accounts         152,888         84,243           Net patient service revenue after provision for doubtful accounts         1,856,671         1,490,009           Other operating revenues and net assets released from restrictions used for operating purposes         148,790         126,625           Total operating revenues         2,005,461         1,616,634           Operating expenses:         859,641         698,752           Salaries, wages, and benefits         859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         -           Contribution of CHHD unrestricted net assets         309,740         -           Derivative ineffecti		\$	2.009.559	1.574.252
accounts         1,856,671         1,490,009           Other operating revenues and net assets released from restrictions used for operating purposes         148,790         126,625           Total operating revenues         2,005,461         1,616,634           Operating expenses:         3859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,5	·			
accounts         1,856,671         1,490,009           Other operating revenues and net assets released from restrictions used for operating purposes         148,790         126,625           Total operating revenues         2,005,461         1,616,634           Operating expenses:         3859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,5	Net nationt service revenue after provision for doubtful			
Other operating revenues and net assets released from restrictions used for operating purposes         148,790         126,625           Total operating revenues         2,005,461         1,616,634           Operating expenses:           Salaries, wages, and benefits         859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         1         2,23,086         1,510,195           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net </td <td>·</td> <td></td> <td>1.856.671</td> <td>1.490.009</td>	·		1.856.671	1.490.009
restrictions used for operating purposes         148,790         126,625           Total operating revenues         2,005,461         1,616,634           Operating expenses:         Salaries, wages, and benefits         859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         82,375         106,439           Nonoperating gains and losses:         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         1         (27,028)         —           Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)			.,000,0.	.,,
Total operating revenues         2,005,461         1,616,634           Operating expenses:         859,641         698,752           Salaries, wages, and benefits         859,641         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net         (71,750)         (72,025)           Change in net assets:         (71,750)         (72,025)           Equ	. •		149 700	126 625
Operating expenses:         Salaries, wages, and benefits         859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net         (71,750)         (72,025)           Change in net assets:         (71,750)         (72,025)           Change in accrued pension benefits other than net periodic benefit costs	restrictions used for operating purposes	-	146,790	120,025
Salaries, wages, and benefits         859,641         698,752           Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net         2,496         —           Revenue and gains in excess of expenses and losses         462,393         85,574           Other changes in net assets:         2,266         (4,429)	Total operating revenues	_	2,005,461	1,616,634
Supplies and other         583,644         427,739           Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         2,095         (2,506)           Distributions and other, net         2,496         —           Revenue and gains in excess of expenses and losses         462,393         85,574           Other changes in net assets:         Equity transfers to University of Chicago, net         (71,750)         (72,025)           Change in accrued pension benefits other than net periodic benefit costs         2,266         (4,429)           Effective portion o	Operating expenses:			
Physician services         251,492         215,727           Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:           Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net         2,496         —           Revenue and gains in excess of expenses and losses         462,393         85,574           Other changes in net assets:         (71,750)         (72,025)           Change in accrued pension benefits other than net periodic benefit costs         2,266         (4,429)	Salaries, wages, and benefits		859,641	698,752
Insurance         17,794         11,324           Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         Investment income (loss) and unrestricted gifts, net         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net         2,496         —           Revenue and gains in excess of expenses and losses         462,393         85,574           Other changes in net assets:         Equity transfers to University of Chicago, net         (71,750)         (72,025)           Change in accrued pension benefits other than net periodic benefit costs         2,266         (4,429)           Effective portion of change in valuation of derivatives         44,863			•	427,739
Interest         39,416         32,940           Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net         2,496         —           Revenue and gains in excess of expenses and losses         462,393         85,574           Other changes in net assets:         Equity transfers to University of Chicago, net         (71,750)         (72,025)           Change in accrued pension benefits other than net periodic benefit costs         2,266         (4,429)           Effective portion of change in valuation of derivatives         44,863         (50,775)           Distributions and other, net         (349)         (65)	Physician services			•
Medicaid provider tax         53,824         36,110           Depreciation and amortization         117,275         87,603           Total operating expenses         1,923,086         1,510,195           Operating revenue in excess of expenses         82,375         106,439           Nonoperating gains and losses:         89,154         (18,359)           Loss on extinguishment of debt         (27,028)         —           Contribution of CHHD unrestricted net assets         309,740         —           Change in fair value of nonhedged derivative instruments         3,561         —           Derivative ineffectiveness on hedged derivative instruments         2,095         (2,506)           Distributions and other, net         2,496         —           Revenue and gains in excess of expenses and losses         462,393         85,574           Other changes in net assets:         Equity transfers to University of Chicago, net         (71,750)         (72,025)           Change in accrued pension benefits other than net periodic benefit costs         2,266         (4,429)           Effective portion of change in valuation of derivatives         44,863         (50,775)           Distributions and other, net         (349)         (65)	Insurance		•	
Total operating expenses 1,923,086 1,510,195 Operating revenue in excess of expenses 82,375 106,439  Nonoperating gains and losses: Investment income (loss) and unrestricted gifts, net 89,154 (18,359) Loss on extinguishment of debt (27,028) — Contribution of CHHD unrestricted net assets 309,740 — Change in fair value of nonhedged derivative instruments 3,561 — Derivative ineffectiveness on hedged derivative instruments 2,095 (2,506) Distributions and other, net 2,496 —  Revenue and gains in excess of expenses and losses 462,393 85,574  Other changes in net assets: Equity transfers to University of Chicago, net (71,750) (72,025) Change in accrued pension benefits other than net periodic benefit costs 2,266 (4,429) Effective portion of change in valuation of derivatives 44,863 (50,775) Distributions and other, net (349) (65)				
Total operating expenses 1,923,086 1,510,195 Operating revenue in excess of expenses 82,375 106,439  Nonoperating gains and losses: Investment income (loss) and unrestricted gifts, net 89,154 (18,359) Loss on extinguishment of debt (27,028) — Contribution of CHHD unrestricted net assets 309,740 — Change in fair value of nonhedged derivative instruments 3,561 — Derivative ineffectiveness on hedged derivative instruments 2,095 (2,506) Distributions and other, net 2,496 —  Revenue and gains in excess of expenses and losses 462,393 85,574  Other changes in net assets: Equity transfers to University of Chicago, net (71,750) (72,025) Change in accrued pension benefits other than net periodic benefit costs 2,266 (4,429) Effective portion of change in valuation of derivatives 44,863 (50,775) Distributions and other, net (349) (65)			•	
Operating revenue in excess of expenses 82,375 106,439  Nonoperating gains and losses:  Investment income (loss) and unrestricted gifts, net 89,154 (18,359) Loss on extinguishment of debt (27,028) — Contribution of CHHD unrestricted net assets 309,740 — Change in fair value of nonhedged derivative instruments 3,561 — Derivative ineffectiveness on hedged derivative instruments 2,095 (2,506) Distributions and other, net 2,496 —  Revenue and gains in excess of expenses and losses 462,393 85,574  Other changes in net assets: Equity transfers to University of Chicago, net (71,750) (72,025) Change in accrued pension benefits other than net periodic benefit costs 2,266 (4,429) Effective portion of change in valuation of derivatives 44,863 (50,775) Distributions and other, net (349) (65)	Depreciation and amortization	_	117,275	87,603
Nonoperating gains and losses:  Investment income (loss) and unrestricted gifts, net Loss on extinguishment of debt Contribution of CHHD unrestricted net assets Change in fair value of nonhedged derivative instruments Derivative ineffectiveness on hedged derivative instruments Distributions and other, net Revenue and gains in excess of expenses and losses  Equity transfers to University of Chicago, net Change in accrued pension benefits other than net periodic benefit costs Effective portion of change in valuation of derivatives Distributions and other, net  (18,359) (27,028)  —  89,154 (18,359) —  20,9740 —  2,095 (2,506) —  Revenue and gains in excess of expenses and losses  462,393 85,574  (71,750) (72,025) Change in accrued pension benefits other than net periodic benefit costs  Effective portion of change in valuation of derivatives  2,266 (4,429) Effective portion of change in valuation of derivatives  44,863 (50,775) Distributions and other, net	Total operating expenses	_	1,923,086	1,510,195
Investment income (loss) and unrestricted gifts, net  Loss on extinguishment of debt  Contribution of CHHD unrestricted net assets  Change in fair value of nonhedged derivative instruments  Derivative ineffectiveness on hedged derivative instruments  Distributions and other, net  Revenue and gains in excess of expenses and losses  Revenue and gains in excess of expenses and losses  Equity transfers to University of Chicago, net  Change in accrued pension benefits other than net periodic  benefit costs  Effective portion of change in valuation of derivatives  Distributions and other, net  (18,359)  (27,028)  —  (27,028)  —  (2,506)  —  (2,506)  —  (71,750)  (72,025)  (72,025)  Change in accrued pension benefits other than net periodic  benefit costs  Effective portion of change in valuation of derivatives  Distributions and other, net  (349)  (65)	Operating revenue in excess of expenses		82,375	106,439
Investment income (loss) and unrestricted gifts, net  Loss on extinguishment of debt  Contribution of CHHD unrestricted net assets  Change in fair value of nonhedged derivative instruments  Derivative ineffectiveness on hedged derivative instruments  Distributions and other, net  Revenue and gains in excess of expenses and losses  Revenue and gains in excess of expenses and losses  Equity transfers to University of Chicago, net  Change in accrued pension benefits other than net periodic  benefit costs  Effective portion of change in valuation of derivatives  Distributions and other, net  (18,359)  (27,028)  —  (27,028)  —  (2,506)  —  (2,506)  —  (71,750)  (72,025)  (72,025)  Change in accrued pension benefits other than net periodic  benefit costs  Effective portion of change in valuation of derivatives  Distributions and other, net  (349)  (65)	Nonoperating gains and losses:			
Contribution of CHHD unrestricted net assets Change in fair value of nonhedged derivative instruments Derivative ineffectiveness on hedged derivative instruments Distributions and other, net  Revenue and gains in excess of expenses and losses  Revenue and gains in excess of expenses and losses  Equity transfers to University of Chicago, net Change in accrued pension benefits other than net periodic benefit costs Effective portion of change in valuation of derivatives Distributions and other, net  309,740   42,095 (2,506)  (71,750) (72,025) (72,025) (72,025) (72,025) (74,429) (75,775) (75,775) (75,775) (75,775) (75,775)			89,154	(18,359)
Change in fair value of nonhedged derivative instruments  Derivative ineffectiveness on hedged derivative instruments  Distributions and other, net  Revenue and gains in excess of expenses and losses  Revenue and gains in excess of expenses and losses  462,393  85,574  Other changes in net assets:  Equity transfers to University of Chicago, net  Change in accrued pension benefits other than net periodic  benefit costs  Effective portion of change in valuation of derivatives  Distributions and other, net  3,561  — (2,506)  (72,025)  (71,750)  (72,025)  (72,025)  (74,429)  (74,429)  (75,775)  (75,775)  (75,775)	Loss on extinguishment of debt		(27,028)	
Derivative ineffectiveness on hedged derivative instruments  Distributions and other, net  Revenue and gains in excess of expenses and losses  A62,393  85,574  Other changes in net assets:  Equity transfers to University of Chicago, net  Change in accrued pension benefits other than net periodic  benefit costs  Effective portion of change in valuation of derivatives  Distributions and other, net  (2,095  (2,506)  (7,750)  (72,025)  (71,750)  (72,025)  (72,025)  (74,429)  (74,429)  (75,775)  (75,775)  (75,005)	Contribution of CHHD unrestricted net assets		309,740	_
Distributions and other, net 2,496 —  Revenue and gains in excess of expenses and losses 462,393 85,574  Other changes in net assets:  Equity transfers to University of Chicago, net (71,750) (72,025)  Change in accrued pension benefits other than net periodic benefit costs 2,266 (4,429)  Effective portion of change in valuation of derivatives 44,863 (50,775)  Distributions and other, net (349) (65)				_
Revenue and gains in excess of expenses and losses 462,393 85,574  Other changes in net assets:  Equity transfers to University of Chicago, net (71,750) (72,025)  Change in accrued pension benefits other than net periodic benefit costs 2,266 (4,429)  Effective portion of change in valuation of derivatives 44,863 (50,775)  Distributions and other, net (349) (65)				(2,506)
Other changes in net assets:  Equity transfers to University of Chicago, net Change in accrued pension benefits other than net periodic benefit costs  Effective portion of change in valuation of derivatives Distributions and other, net  (71,750) (72,025) (72,025) (74,429) (4,429) (4,429) (50,775) (65)	Distributions and other, net	_	2,496	
Equity transfers to University of Chicago, net (71,750) (72,025)  Change in accrued pension benefits other than net periodic benefit costs 2,266 (4,429)  Effective portion of change in valuation of derivatives 44,863 (50,775)  Distributions and other, net (349) (65)	Revenue and gains in excess of expenses and losses		462,393	85,574
Equity transfers to University of Chicago, net (71,750) (72,025)  Change in accrued pension benefits other than net periodic benefit costs 2,266 (4,429)  Effective portion of change in valuation of derivatives 44,863 (50,775)  Distributions and other, net (349) (65)	Other changes in net assets:			
benefit costs 2,266 (4,429) Effective portion of change in valuation of derivatives 44,863 (50,775) Distributions and other, net (349) (65)			(71,750)	(72,025)
Effective portion of change in valuation of derivatives44,863(50,775)Distributions and other, net(349)(65)	Change in accrued pension benefits other than net periodic			
Distributions and other, net (349) (65)			2,266	(4,429)
	Effective portion of change in valuation of derivatives		44,863	(50,775)
Increase (decrease) in unrestricted net assets \$ 437,423 (41,720)	Distributions and other, net	_	(349)	(65)
	Increase (decrease) in unrestricted net assets	\$_	437,423	(41,720)

# Consolidated Statements of Changes in Net Assets

# Years ended June 30, 2017 and 2016

(In thousands)

	_	2017	2016
Unrestricted net assets:			
Revenue and gains in excess of expenses and losses	\$	462,393	85,574
Equity transfers to University of Chicago, net		(71,750)	(72,025)
Change in accrued pension benefits other than net periodic			
benefit cost		2,266	(4,429)
Effective portion of change in valuation of derivatives		44,863	(50,775)
Distributions and other, net	_	(349)	(65)
Increase (decrease) in unrestricted net assets	_	437,423	(41,720)
Temporarily restricted net assets:			
Contributions		3,437	3,677
Net assets released from restrictions used for operating purposes		(6,518)	(5,501)
Investment income (loss)		7,582	(2,425)
Contribution of CHHD temporarily restricted net assets		4,035	_
Other, net	_		65
Increase (decrease) in temporarily restricted net assets	_	8,536	(4,184)
Permanently restricted net assets:			
Contribution of CHHD permanently restricted net assets		9,087	_
Contributions and other	_	246	10
Increase in permanently restricted net assets		9,333	10
Change in net assets		455,292	(45,894)
Net assets at beginning of year		1,315,653	1,361,547
Net assets at end of year	\$	1,770,945	1,315,653

# Consolidated Statements of Cash Flows

Years ended June 30, 2017 and 2016

Cash flows from operating activities:         \$ 455,292         (45,894)           Adjustments to reconcile change in net assets to net cash provided by operating activities:         (18,303)         35,951           Net change in unrealized gains and losses on investments         (18,303)         35,951           Equity transfers to University of Chicago         71,750         72,025           Restricted contributions and investment return         (16,660)         (56,460)           Net change in valuation of derivatives         (48,802)         54,970           Contribution of CHHD net assets         (322,662)         —           Change in accrued pension benefits other than net period benefit cost and other         (22,666)         4,429           Loss on disposal of assets         91         853           Provision for doubtrul accounts         (51,888)         84,243           Loss on extinguishment of debt         27,028         —           Not assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities         (264,110)         (62,908)           Other assets         (28,110)         (162,908)           Accounts payable and accrued expenses         35,106         6,985		 2017	2016
Change in net assets   Adjustments to reconcile change in net assets to net cash provided by operating activities:   Net change in unrealized gains and losses on investments   (18,303)   35,951     Equity transfers to University of Chicago   71,750   72,025     Restricted contributions and investment return   (11,265)   (1,262)     Realized gains on investments   (56,460)   (6,451)     Net change in valuation of derivatives   (362,662)   (-2,661)     Net change in valuation of derivatives   (362,662)   (-2,661)     Change in accrued pension benefits other than net period benefit cost and other   (2,266)   (4,29)     Change in accrued pension benefits other than net period benefit cost and other   (2,266)   (4,29)     Loss on disposal of assets   91   853     Provision for doubtful accounts   (5,2888   84,243     Loss on extinguishment of debt   (7,088   -2,267   (7,088   -2,267   (7,578   (7,088   -2,267   (7,578   (7,588	Cash flows from operating activities:		
Activities:   Net change in unrealized gains and losses on investments   18,303   35,951		\$ 455,292	(45,894)
Equity transfers to University of Chicago         71,750         72,025           Restricted contributions and investment return         (11,265)         (1,262)           Realized gains on investments         (56,460)         (6,451)           Net change in waluation of derivatives         (322,862)         —           Change in accrued pension benefits other than net period benefit cost and other         (2,266)         4,429           Loss on disposal of assets         91         853           Provision for doubtful accounts         152,888         84,243           Loss on extinguishment of debt         27,028         —           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         (17,275)         87,603           Changes in assets and liabilities:         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         37,291           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (17,32) <t< td=""><td></td><td></td><td></td></t<>			
Restricted opins on investments         (11,265)         (1,262)           Realized gains on investments         (6,461)         (6,451)           Net change in valuation of derivatives         (48,820)         54,970           Contribution of CHHD net assets         (32,2862)         —           Change in accrued pension benefits other than net period benefit cost and other         (32,2862)         —           Loss on disposal of assets         91         853           Provision for doubtful accounts         152,888         84,243           Loss on extinguishment of debt         27,028         —           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         (1,732)         2,841 <t< td=""><td>Net change in unrealized gains and losses on investments</td><td>(18,303)</td><td>35,951</td></t<>	Net change in unrealized gains and losses on investments	(18,303)	35,951
Restricted opins on investments         (11,265)         (1,262)           Realized gains on investments         (6,461)         (6,451)           Net change in valuation of derivatives         (48,820)         54,970           Contribution of CHHD net assets         (32,2862)         —           Change in accrued pension benefits other than net period benefit cost and other         (32,2862)         —           Loss on disposal of assets         91         853           Provision for doubtful accounts         152,888         84,243           Loss on extinguishment of debt         27,028         —           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         (1,732)         2,841 <t< td=""><td>Equity transfers to University of Chicago</td><td>71,750</td><td>72,025</td></t<>	Equity transfers to University of Chicago	71,750	72,025
Realized gains on investments         (56,460)         (6,451)           Net change in valuation of derivatives         (322,862)         54,970           Contribution of CHHD net assetts         (322,862)            Change in accrued pension benefits other than net period benefit cost and other         (2,266)         4,429           Loss on disposal of assetts         91         853           Provision for doubtful accounts         152,888         84,243           Loss on extinguishment of debt         27,028            Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:          (264,110)         (162,908)           Other assets         (25,472)         (27,551)         6,985            Due to the University of Chicago         6,579         (37,291)          1,732)         2,841           Other liabilities         (1,732)         2,841          1,4133           1,414           Cash flows from investing activities:          1,41,41          1,41,41           Change in assets and explain activities		•	
Net change in valuation of derivatives         (34,80)         54,970           Contribution of CHPID net assets         (322,862)         4,429           Loss on disposal of assets         91         853           Provision for doubtful accounts         152,888         84,243           Loss on extinguishment of debt         27,028         —           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         (264,110)         (162,908)           Patient accounts receivable, net         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,958           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         (1,732)         2,841           Other liabilities         (1,732)         2,841           Other liabilities         (1,462,91)         (1,442)           Payable and provided by operating activities         <	Realized gains on investments	, ,	, , ,
Contribution of CHHD net assets         (322,862)         —           Change in accrued pension benefits other than net period benefit cost and other         (2,266)         4,429           Change in accrued pension benefits other than net period benefit cost and other         152,888         833           Provision for doubitful accounts         152,888         84,243           Loss on extinguishment of debt         27,028         —           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (17,732)         2,841           Other liabilities         (17,322)         2,841           Other liabilities         (17,332)         2,841           Other liabilities         (17,332)         2,841           Other liabilities         (39,310)         39,32 <tr< td=""><td>•</td><td>, ,</td><td>, , ,</td></tr<>	•	, ,	, , ,
Change in accrued pension benefits other than net period benefit cost and other         (2,266)         4,429           Loss on disposal of assets         91         853           Provision for doubtful accounts         152,888         84,243           Loss on extinguishment of debt         27,028         -           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         117,275         87,603           Charges in assets and liabilities:         (264,110)         (162,908)           Other assets         (25,472)         (27,511)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         (1,732)         2,841           Other liabilities         (1,732)         2,841           Other liabilities         (1,7135)         (234,191)           Cash flows from investing activities         (1,70,135)         (234,191)           Change in con	· · · · · · · · · · · · · · · · · · ·	, ,	_
Loss on disposal of assets   91   853     Provision for doubful accounts   152,888   84,243     Loss on extinguishment of debt   27,028   — 1     Net assets released from restrictions for operations   117,275   87,603     Depreciation and amortization   117,275   87,603     Changes in assets and liabilities:   225,472   (27,551)     Patient accounts receivable, net   (284,110   (162,908)     Other assets   (25,472   (27,551)     Accounts payable and accrued expenses   35,105   6,985     Due to the University of Chicago   6,579   37,291     Estimated settlements with third-party payors   16,750   23,267     Self-insurance liabilities   1,6750   23,267     Self-insurance liabilities   4,651   4,133     Net cash provided by operating activities   4,651   4,133     Net cash provided by operating activities   142,637   101,444     Cash flows from investing activities:   170,135   (234,191)     Purchases of property, plant, and equipment   (170,135   (234,191)   (234,191)     Change in construction payables   (39,109   26,892     Physician practice acquisitions   — (1,447)     Purchases of investments   (402,496   (46,138)     Sales of investments   (402,496   (46,138)     Sales of investments   (402,496   (46,138)     Sales of investments   (402,496   (46,138)     Cash flows from financing activities   (28,003   — Perpendic of the contribution of CHHD   (28,004   — Perpendic of the contribution of CHHD		, ,	4.429
Provision for doubtful accounts         152,888         84,243           Loss on extinguishment of debt         27,028         —           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amoritzation         117,275         87,603           Changes in assets and liabilities:         —           Patient accounts receivable, net         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         (1,70,135)         (23,4191)           Purchases of property, plant, and equipment         (170,135)         (234,191) <td< td=""><td>· · · · · · · · · · · · · · · · · · ·</td><td> ,</td><td>, -</td></td<>	· · · · · · · · · · · · · · · · · · ·	,	, -
Loss on extinguishment of debt         27,028         —           Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         ****         ****         2(26,410)         (162,908)           Other assets         (25,472)         (27,551)         Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)         Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         4,651         4,133         4,133         101,444           Cash flows from investing activities         142,637         101,444           Cash flows from investing activities:         ***         101,447           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables <td< td=""><td>·</td><td></td><td></td></td<>	·		
Net assets released from restrictions for operations         6,518         5,501           Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         117,275         87,603           Patient accounts receivable, net         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,995           Due to the University of Chicago         6,679         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         2         101,444           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         (402,496)         (46,138)           Sales of investments         (402,496)         (46,138)           Sales of investments         (402,496)         (46,138)           Sales of i		•	O-1,2-10 —
Depreciation and amortization         117,275         87,603           Changes in assets and liabilities:         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         — (1,447)           Purchases of property, plant, and equipment         (402,496)         (46,138)           Sales of investments         (402,496)         (46,138)           Sales of investments         488,139         100,389           Sales of investments         488,139         101,389           Cash received from contribution of CHHD         28,003         —           Portices acquisitions         (20,009)	· · · · · · · · · · · · · · · · · · ·	•	5 501
Changes in assets and liabilities:         (264,110)         (162,908)           Patient accounts receivable, net         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         2         2234,191           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         ————————————————————————————————————	·		•
Patient accounts receivable, net         (264,110)         (162,908)           Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         """         101,444           Cash flows from investing activities:         """         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         """         (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         """           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         (20,009)         (14,824)	·	117,275	07,000
Other assets         (25,472)         (27,551)           Accounts payable and accrued expenses         35,105         6,885           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         Total payables         (170,135)         (234,191)           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,882           Physician practice acquisitions         — (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         (402,496)         (46,138)           Sales of investments         (28,003)         —           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         (220,069)         (14,824)           Draws on	· · · · · · · · · · · · · · · · · · ·	(264 110)	(162 908)
Accounts payable and accrued expenses         35,105         6,985           Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         2         101,444           Cash flows from investing activities:         (39,109)         26,892           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         — (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         (402,496)         (46,138)           Sales of investments         (495,598)         (153,990)           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         256,396         —           Poxyments on long-term obligations         (220,698)         (14,824)           Draws on revolving credit faci	·	, ,	, , , ,
Due to the University of Chicago         6,579         (37,291)           Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         ***         ***           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         - (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         (402,496)         (46,138)           Sales of investments         (95,598)         (153,990)           Cash received from contribution of CHHD         28,003         -           Net cash used in investing activities         **         **           Proceeds from financing activities         (95,598)         (153,990)           Cash flows from financing activities         (220,069)         (14,824)           Draws on revolving credit facility         3,000         -           Payments of bond issuance costs		` ' '	` ' '
Estimated settlements with third-party payors         16,750         23,267           Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         8         12,234           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         —         (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         (220,069)         (14,824)           Proceeds from issuance of long-term debt, including bond premium         256,396         —           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —           Payments of bond issuance costs         (2,252)         —		•	
Self-insurance liabilities         (1,732)         2,841           Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         \$\text{Purchases of property, plant, and equipment}}\$			, , ,
Other liabilities         4,651         4,133           Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         \$\text{Purchases of property, plant, and equipment}} \tag{(39,109)} \tag{(39,109)} \tag{(234,191)} (234			·
Net cash provided by operating activities         142,637         101,444           Cash flows from investing activities:         ***           Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         —** (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —**           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         28,003         —**           Proceeds from issuance of long-term debt, including bond premium         256,396         —**           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —**           Payments of bond issuance costs         (2,252)         —*           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1		, ,	•
Cash flows from investing activities:         Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         — (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         —         —           Proceeds from issuance of long-term debt, including bond premium         256,396         —           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —           Payments of bond issuance costs         (2,252)         —           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1,262           Net cash used in financing activities         (29,928)         (91,088)           Net increase (dec	Other habilities	 4,001	4,133
Purchases of property, plant, and equipment         (170,135)         (234,191)           Change in construction payables         (39,109)         26,892           Physician practice acquisitions         (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         —         —           Proceeds from issuance of long-term debt, including bond premium         256,396         —           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —           Payments of bond issuance costs         (2,252)         —           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1,262           Net cash used in financing activities         (29,928)         (91,088)           Net increase (decrease) in cash and cash equivalents         17,1	Net cash provided by operating activities	 142,637	101,444
Change in construction payables         (39,109)         26,892           Physician practice acquisitions         —         (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         —         256,396         —           Proceeds from issuance of long-term debt, including bond premium         256,396         —           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —           Payments of bond issuance costs         (2,252)         —           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1,262           Net cash used in financing activities         (29,928)         (91,088)           Net increase (decrease) in cash and cash equivalents         17,111         (143,634)           Cash and cash equivalent	Cash flows from investing activities:		
Physician practice acquisitions         —         (1,447)           Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         —         256,396         —           Proceeds from issuance of long-term debt, including bond premium         256,396         —           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —           Payments of bond issuance costs         (2,252)         —           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1,262           Net cash used in financing activities         (29,928)         (91,088)           Net increase (decrease) in cash and cash equivalents         17,111         (143,634)           Cash and cash equivalents:         20,335         163,969	Purchases of property, plant, and equipment	(170,135)	(234,191)
Purchases of investments         (402,496)         (46,138)           Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         —           Proceeds from issuance of long-term debt, including bond premium         256,396         —           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —           Payments of bond issuance costs         (2,252)         —           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1,262           Net cash used in financing activities         (29,928)         (91,088)           Net increase (decrease) in cash and cash equivalents         17,111         (143,634)           Cash and cash equivalents:         20,335         163,969	Change in construction payables	(39,109)	26,892
Sales of investments         488,139         100,894           Cash received from contribution of CHHD         28,003         —           Net cash used in investing activities         (95,598)         (153,990)           Cash flows from financing activities         Proceeds from issuance of long-term debt, including bond premium         256,396         —           Payments on long-term obligations         (220,069)         (14,824)           Draws on revolving credit facility         3,000         —           Payments of bond issuance costs         (2,252)         —           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1,262           Net cash used in financing activities         (29,928)         (91,088)           Net increase (decrease) in cash and cash equivalents         17,111         (143,634)           Cash and cash equivalents:         20,335         163,969	Physician practice acquisitions	_	(1,447)
Cash received from contribution of CHHD28,003—Net cash used in investing activities(95,598)(153,990)Cash flows from financing activities256,396—Proceeds from issuance of long-term debt, including bond premium256,396—Payments on long-term obligations(220,069)(14,824)Draws on revolving credit facility3,000—Payments of bond issuance costs(2,252)—Equity transfers to the University of Chicago, net(71,750)(72,025)Net assets released from restriction for operations(6,518)(5,501)Restricted contributions and investment return11,2651,262Net cash used in financing activities(29,928)(91,088)Net increase (decrease) in cash and cash equivalents17,111(143,634)Cash and cash equivalents:20,335163,969	Purchases of investments	(402,496)	(46,138)
Net cash used in investing activities (95,598) (153,990)  Cash flows from financing activities  Proceeds from issuance of long-term debt, including bond premium 256,396 —  Payments on long-term obligations (220,069) (14,824)  Draws on revolving credit facility 3,000 —  Payments of bond issuance costs (2,252) —  Equity transfers to the University of Chicago, net (71,750) (72,025)  Net assets released from restriction for operations (6,518) (5,501)  Restricted contributions and investment return 11,265 1,262  Net cash used in financing activities (29,928) (91,088)  Net increase (decrease) in cash and cash equivalents 17,111 (143,634)  Cash and cash equivalents:  Beginning of year 20,335 163,969	Sales of investments	488,139	100,894
Cash flows from financing activities Proceeds from issuance of long-term debt, including bond premium Payments on long-term obligations Payments on revolving credit facility Payments of bond issuance costs Payments of bond	Cash received from contribution of CHHD	 28,003	
Proceeds from issuance of long-term debt, including bond premium  Payments on long-term obligations  Cash and cash equivalents:  Perport of long-term debt, including bond premium  256,396  (220,069) (14,824)  (220,069) (14,824)  3,000  — (220,069) (14,824)  3,000 — (22,252) — (2,252) — (71,750) (72,025)  (6,518) (5,501)  Restricted contributions and investment return 11,265 1,262  Net cash used in financing activities (29,928) (91,088)  Cash and cash equivalents:  Beginning of year  20,335 163,969	Net cash used in investing activities	 (95,598)	(153,990)
Payments on long-term obligations(220,069)(14,824)Draws on revolving credit facility3,000—Payments of bond issuance costs(2,252)—Equity transfers to the University of Chicago, net(71,750)(72,025)Net assets released from restriction for operations(6,518)(5,501)Restricted contributions and investment return11,2651,262Net cash used in financing activities(29,928)(91,088)Net increase (decrease) in cash and cash equivalents17,111(143,634)Cash and cash equivalents:20,335163,969	Cash flows from financing activities		
Draws on revolving credit facility Payments of bond issuance costs  Equity transfers to the University of Chicago, net Net assets released from restriction for operations Restricted contributions and investment return Net cash used in financing activities Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents: Beginning of year  3,000 (72,025) (	Proceeds from issuance of long-term debt, including bond premium	256,396	_
Payments of bond issuance costs         (2,252)         —           Equity transfers to the University of Chicago, net         (71,750)         (72,025)           Net assets released from restriction for operations         (6,518)         (5,501)           Restricted contributions and investment return         11,265         1,262           Net cash used in financing activities         (29,928)         (91,088)           Net increase (decrease) in cash and cash equivalents         17,111         (143,634)           Cash and cash equivalents:         20,335         163,969	Payments on long-term obligations	(220,069)	(14,824)
Equity transfers to the University of Chicago, net       (71,750)       (72,025)         Net assets released from restriction for operations       (6,518)       (5,501)         Restricted contributions and investment return       11,265       1,262         Net cash used in financing activities       (29,928)       (91,088)         Net increase (decrease) in cash and cash equivalents       17,111       (143,634)         Cash and cash equivalents:       20,335       163,969	Draws on revolving credit facility	3,000	_
Net assets released from restriction for operations Restricted contributions and investment return(6,518) 11,262(5,501) 1,262Net cash used in financing activities Net increase (decrease) in cash and cash equivalents(29,928)(91,088)Cash and cash equivalents: Beginning of year20,335163,969	Payments of bond issuance costs	(2,252)	_
Restricted contributions and investment return 11,265 1,262  Net cash used in financing activities (29,928) (91,088)  Net increase (decrease) in cash and cash equivalents 17,111 (143,634)  Cash and cash equivalents:  Beginning of year 20,335 163,969	Equity transfers to the University of Chicago, net	(71,750)	(72,025)
Net cash used in financing activities(29,928)(91,088)Net increase (decrease) in cash and cash equivalents17,111(143,634)Cash and cash equivalents: Beginning of year20,335163,969	Net assets released from restriction for operations	(6,518)	(5,501)
Net increase (decrease) in cash and cash equivalents 17,111 (143,634)  Cash and cash equivalents: Beginning of year 20,335 163,969	Restricted contributions and investment return	 11,265	1,262
Cash and cash equivalents: Beginning of year 20,335 163,969	Net cash used in financing activities	 (29,928)	(91,088)
Beginning of year         20,335         163,969	Net increase (decrease) in cash and cash equivalents	17,111	(143,634)
Beginning of year         20,335         163,969	Cash and cash equivalents:		
End of year \$ 37,446 20,335	·	 20,335	163,969
	End of year	\$ 37,446	20,335

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

## (1) Organization and Basis of Presentation

The accompanying consolidated financial statements represent the accounts of The University of Chicago Medical Center and its affiliates (the System). The University of Chicago Medical Center (UCMC) is the parent of an integrated nonprofit health care organization, partnering with the University of Chicago Biological Sciences Division, the University of Chicago Pritzker School of Medicine, and the University of Chicago Physicians Group to provide world-class medical care in an academic setting. UCMC operates the Center for Care and Discovery, the Bernard Mitchell Hospital, the Chicago Lying-In Hospital, the University of Chicago Comer Children's Hospital, the Duchossois Center for Advanced Medicine, the University of Chicago Medicine Care Network, the UCM Community Health and Hospital Division, Inc. (CHHD), and various other outpatient clinics and treatment areas. Additional affiliated entities include the University of Chicago Medicine Care Network, which provides support and healthcare services in the greater Chicago region to support the healthcare needs to the community, and the UCMC Title Holding Corporation and UCMC Title Holding Corporation II NFP, which cooperatively invest in facilities and equipment for the advancement of patient care.

On October 1, 2016, UCMC acquired Ingalls Health System (IHS) through an affiliation and member substitution. As a result of this transaction, IHS became a wholly owned subsidiary of UCMC through the newly created CHHD of UCMC. Accordingly, the 2017 consolidated system statement of operations and changes in unrestricted net assets includes the operating activity of IHS for the nine-month period from October 1, 2016 through June 30, 2017.

The University of Chicago (the University), as the sole corporate member of UCMC, elects UCMC's Board of Trustees and approves its bylaws. The UCMC President reports to the University's Executive Vice President for Medical Affairs. The relationship between UCMC and the University is defined in the Medical Center bylaws, an affiliation agreement, an operating agreement, and several leases. See note 4 for agreements and transactions with the University.

## (2) Summary of Significant Accounting Policies

## (a) Principles of Consolidation

The consolidated financial statements of the System have been prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (GAAP). All significant intercompany accounts and transactions have been eliminated in consolidation.

## (b) New Accounting Pronouncements

During 2017, the System adopted the provisions of Accounting Standards Update (ASU) No. 2015-13, *Interest – Imputation of Interest* (ASU 2015-03). ASU 2015-03 amends Accounting Standards Codification (ASC) Topic 835, *Interest* by requiring debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with the debt discounts and premiums. The adoption of the ASU 2015-03 was effective for the System for the year ended June 30, 2017.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

During 2017, the System adopted ASU No. 2017-07, Compensation – Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This guidance requires the service cost component of net periodic benefit cost for pension and other postretirement benefit costs be presented as a component part of employee benefit expense. The other components of net periodic benefit cost, such as interest, expected return on plan assets, and amortization of other actuarially determined amounts, are required to be presented as a nonoperating change in unrestricted net assets. The System adopted the changes for the year ended June 30, 2017.

In August 2016, Financial Accounting Standards Board (FASB) issued ASU No. 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities* (ASU 2016-14). ASU 2016-14 represents phase 1 of FASB's not-for-profit financial reporting project and results reduce the number of net asset classes, require expense presentation by functional and natural classification, require quantitative and qualitative information in liquidity, retain the option to present the cash flow statement on a direct or indirect method, as well as include various other additional disclosure requirements. The System is assessing the impacts on financial statement presentation and disclosures for this ASU.

In May 2014, FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*. This ASU establishes principles for reporting useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from the entity's contracts with customers. Particularly, that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The requirements of this statement are effective for the System for the year ending June 30, 2019. The System expects to record a decrease in net patient service revenue and a corresponding decrease in the provision for uncollectible accounts upon adoption of the standard. However, the System is still in the process of assessing the impacts on financial statement presentation and disclosures for this ASU.

In February 2016, FASB issues ASU No. 2016-02, *Leases* (ASU 2016-02). ASU 2016-02 requires entities to recognize all leased assets as assets on the balance sheet with a corresponding liability resulting in a gross up of the balance sheet. Entities will also be required to present additional disclosures as the nature and extent of leasing activities. ASU 2016-02 is effective for nonpublic business entities for the annual reporting period beginning after December 31, 2018. The requirements of this statement are effective for the System for the year ending June 30, 2020. The System has not evaluated the impact of this statement.

#### (c) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

## (d) Community Benefits

The System's policy is to treat patients in immediate need of medical services without regard to their ability to pay for such services, including patients transferred from other hospitals under the provisions

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

of the Emergency Medical Treatment and Active Labor Act. UCMC also accepts patients through the Perinatal and Pediatric Trauma Networks without regard to their ability to pay for services.

The System developed a Financial Assistance Policy (the Policy) under which patients are offered discounts of up to 100% of charges on a sliding scale. The Policy is based both on income as a percentage of the Federal Poverty Level guidelines and the charges for services rendered. The Policy also contains provisions that are responsive to those patients subject to catastrophic healthcare expenses. Since the System does not pursue collection of these amounts, they are not reported as net patient service revenue. The cost of providing care under this Policy, along with the unreimbursed cost of government sponsored indigent healthcare programs, unreimbursed cost to support education, clinical research, and other community programs for the years ended June 30, 2017 and 2016, are reported in note 6.

# (e) Fair Value of Financial Instruments

Fair value is defined as the price that the System would receive upon selling an asset or pay to settle a liability in an orderly transaction between market participants.

The System uses a framework for measuring fair value that includes a hierarchy that categorizes and prioritizes the sources used to measure and disclose fair value. This hierarchy is broken down into three levels based on inputs that market participants would use in valuing the financial instruments based on market data obtained from sources independent of the System. Inputs refer broadly to the assumptions that market participants would use in pricing the asset, including assumptions about risk. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset developed based on the best information available. The three tier hierarchy of inputs is summarized in the three broad levels as follows:

Level 1 – Quoted market prices in active markets for identical investments

Level 2 – Inputs other than quoted prices for similar investments in active markets, quoted prices for identical or similar investments in markets that are not active, or inputs other than quoted prices that are observable including model-based valuation techniques

Level 3 – Valuation techniques that use significant inputs that are unobservable because they trade infrequently or not at all

# (f) Cash and Cash Equivalents

Cash equivalents include U.S. Treasury notes, commercial paper, and corporate notes with original maturities of three months or less, excluding investments whose use is limited or restricted.

# (g) Inventory

The System values inventories at the lower of cost or market, using the first-in, first-out method. During 2016, UCMC changed its non-GAAP policy for recording certain inventory. This change resulted in an

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

\$8,200 increase in inventory at June 30, 2016 and a corresponding \$8,200 reduction in supplies and other expense in the accompanying 2016 consolidated statement of operations and changes in unrestricted net assets.

## (h) Investments

Investments are classified as trading securities. As such, investment income or loss (including realized or unrealized gains and losses on investments, interest, and dividends) is included in excess of revenue and gains over expenses and losses unless the income is restricted by donor or law.

Investments are recorded in the consolidated financial statements at estimated fair value. If an investment is held directly by an entity and an active market with quoted prices exists, the market price of an identical security is used as reported fair value. Reported fair values for shares in mutual funds are based on share prices reported by the funds as of the last business day of the fiscal year. The System's interests in alternative investment funds, such as private debt, private equity, real estate, natural resources, and absolute return, are generally reported at the net asset value (NAV) reported by the fund managers, which is used as a practical expedient to estimate the fair value, unless it is probable that all or a portion of the investment will be sold for an amount different from NAV. As of June 30, 2017 and 2016, the System had no plans to sell investments at amounts different from NAV.

A significant portion of the System's investments are part of the University's Total Return Investment Pool (TRIP). The System accounts for its investments in TRIP on the fair value method based on its share of the underlying securities and, accordingly, records the investment activity as if the System owned the investments directly using the fair value option election. The University does not engage directly in unhedged speculative investments; however, the Board of the University has authorized the use of derivative investments to adjust market exposure within asset class ranges.

A summary of the inputs used in valuing the System's investments as of June 30, 2017 and 2016 is included in note 7.

## (i) Endowment Funds with Deficits

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (deficit). When donor endowment deficits exist, they are classified as a reduction of unrestricted net assets. As of June 30, 2017 and 2016, endowments in deficit positions were \$0 and \$65, respectively.

## (j) Investments Limited as to Use

Investments limited as to use primarily include assets held by trustees under debt and other agreements and designated assets set aside by the Board of Trustees for future capital improvements and other specific purposes, over which the Board retains control and may at its discretion subsequently use for other purposes. Investments limited as to use also include investments held under swap collateral posting requirements, investments under the workers' compensation self-insurance trust funds, and investments whose use is restricted by donors. Investments limited as to use are reported as unrestricted net assets. Investments whose use is restricted by donors are reported as temporarily restricted or permanently restricted.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

### (k) Derivative Instruments

The System accounts for derivatives and hedging activities in accordance with ASC Topic 815, Derivatives and Hedging, which requires that all derivative instruments be recorded as either assets or liabilities in the balance sheet at their respective fair values.

For hedging relationships, the System formally documents the hedging relationship and its risk management objective and strategy for understanding the hedge, the hedging instrument, the nature of the risk being hedged, how the hedging investment's effectiveness in offsetting the hedged risk will be assessed, and a description of the method for measuring ineffectiveness. This process includes linking all derivatives that are presented as cash flow hedges to specific assets and liabilities in the balance sheet.

# (I) Property, Plant, and Equipment

Property, plant, and equipment are reported on the basis of cost less accumulated depreciation and amortization. Depreciation of property, plant, and equipment is calculated by use of the straight-line method at rates intended to depreciate the cost of assets over their estimated useful lives, which generally range from three to eighty years. Interest costs incurred during the period of construction of capital assets are capitalized as a component of the cost of acquiring those assets.

Gifts of long-lived assets with explicit restrictions by donors that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted contributions. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

The System periodically assesses the recoverability of long-lived assets (including property, plant, and equipment) when indications of potential impairment, based on estimated, undiscounted future cash flows exist. Management considers factors, such as current results, trends, and future prospects, in addition to other economic factors, in determining whether there is an impairment of the asset.

## (m) Asset Retirement Obligation

The System recognizes a liability for the fair value of a legal obligation to perform asset retirement activities in which the timing or method of settlement are conditional on a future event if the amount can be reasonably estimated. Upon recognition of a liability, the asset retirement cost is recorded as an increase in the carrying value of the related long-lived asset and then depreciated over the life of the asset. The System's asset retirement obligations arise primarily from regulations that specify how to dispose of asbestos if facilities are demolished or undergo major renovations or repairs. The System's obligation to remove asbestos was estimated using site-specific surveys where available and a per square foot estimate where surveys were unavailable.

## (n) Other Assets and Liabilities

Goodwill and intangible assets principally relate to physician practice acquisitions. Intangible assets are being amortized over a period, generally not to exceed five years. Intangible assets were \$703 and \$996 for the years ended June 30, 2017 and 2016, respectively, and are included within other assets,

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

net in the consolidated balance sheets. The System follows the provisions of ASC Subtopic 958-805, *Not-for-Profit Entities – Business* Combinations, which discontinued the amortization of goodwill. Under ASC Subtopic 958-805, goodwill is to be reviewed for impairment at least annually using a two-step test. Goodwill at June 30, 2017 and 2016 was \$1,392 and \$1,140, respectively, and is included in other assets, net within the consolidated balance sheets. No goodwill impairment was recorded by the System in 2017 and 2016.

## (o) Net Assets

Net assets are classified as either permanently or temporarily restricted when the use of the assets is limited by outside parties or as unrestricted net assets when outside parties place no restrictions on the use of the assets or when the assets arise as a result of the operations of the System.

Unconditional promises to give cash and other assets to the System are reported at fair value at the date the promise is received. Pledges receivable to be collected after one year are discounted using a risk-adjusted interest rate at the time the pledge is made. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received. The gifts are reported as either temporarily or permanently restricted support if they are received with donor stipulations that limits the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and reported as operating revenue in the statements of operations and changes in unrestricted net assets if restricted for operating purposes and as an increase to unrestricted net assets if restricted to purchase property, plant, and equipment. Gifts for which donors have not stipulated restrictions, as well as contributions for which donors have not stipulated restrictions that are met within the same reporting period, are reported as other operating revenue.

# (p) Statement of Operations

All activities of the System deemed by management to be ongoing, major, and central to the provision of healthcare services are reported as operating revenue and expenses.

The consolidated statement of operations and changes in unrestricted net assets includes revenue and gains in excess of expenses and losses. Changes in unrestricted net assets that are excluded from revenue and gains in excess of expenses and losses include transfers to the University, contributions of long-lived assets released from restrictions (including assets acquired using contributions which by donor restriction were to be used for acquisition of System assets), the effective portion of changes in the valuation of derivatives, and change in accrued pension benefits other than net periodic benefit costs, distributions and other.

### (q) Net Patient Service Revenue, Accounts Receivable, and Allowance for Doubtful Accounts

The System maintains agreements with the Centers for Medicare and Medicaid Services under the Medicare Program, Blue Cross and Blue Shield of Illinois, Inc. (Blue Cross), and the State of Illinois under the Medicaid Program and various managed care payors that govern payment to the System for services rendered to patients covered by these agreements. The agreements generally provide for per

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

case or per diem rates or payments based on allowable costs, subject to certain limitations, for inpatient care and discounted charges or fee schedules for outpatient care.

Net patient service revenue is reported at estimated net realizable amounts from patients, third-party payors, and others for services rendered and include estimated retroactive revenue adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and System estimates are adjusted in future periods as adjustments become known or as years are no longer subject to System audits, reviews and investigations. Adjustments to prior year estimates for these items resulted in an increase in net patient service revenue of \$8,058 in 2017 and \$3,874 in 2016. Contracts, laws, and regulations governing Medicare, Medicaid, and Blue Cross are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.

The process for estimating the ultimate collectibility of receivables involves significant assumptions and judgment. The System has implemented a standardized approach to this estimation based on the payor classification and age of outstanding receivables. Account balances are written off against the allowance when management feels it is probable the receivable will not be recovered. The use of historical collection experience is an integral part of the estimation of the reserve for doubtful accounts. Revisions in the reserve for doubtful accounts are recorded as adjustments to the provision for doubtful accounts.

## (r) Hospital Assessment Program/Medicaid Provider Tax

In December 2008, the State of Illinois, after receiving approval by the federal government, implemented a hospital assessment program. The program assessed hospitals a provider tax based on occupied bed days and provided increases in hospitals' Medicaid payments. In 2017, reimbursement under the assessment programs resulted in a net increase of \$32,560 in operating income, which includes \$79,054 in Medicaid payments included in net patient service revenue offset by \$46,494 in Medicaid provider tax expense. In 2016, reimbursement under the assessment programs resulted in a net increase of \$29,190 in operating income, which includes \$65,300 in Medicaid payments included in net patient service revenue offset by \$36,110 in Medicaid provider tax expense.

## (s) Affordable Care Act (ACA)

In March 2010, the federal government passed the ACA, which expanded Medicaid coverage to millions of low-income Americans and made improvements to both the Medicaid and the Children's Health Insurance Program. Beginning in 2014, coverage for newly eligible adults would be funded by the federal government for three years. The System recognized \$16,239 and \$14,300 of net patient service revenue in 2017 and 2016, respectively, under this new law. Due to the timing of actual payments, UCMC recorded a receivable of \$4,440 and \$4,000 as of June 30, 2017 and 2016, respectively.

Beginning in 2016, coverage for newly eligible adults was expanded to include adults covered by an authorized Medicaid managed care organization. The coverage would be funded by the federal government for two years. For the year ended June 30, 2017, the System recognized as reimbursement under the new legislation a net increase of \$19,904 in operating income, which includes

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

\$27,234 in Medicaid payments included in net patient service revenue offset by \$7,330 in Medicaid provider tax expenses. \$7,604 of the net revenue from Medicaid payments received and recognized in fiscal year 2017 were retroactive payments related to fiscal year 2016.

## (t) Income Taxes

The System applies ASC Topic 740, *Income Taxes* (ASC 740), which clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements. ASC 740 prescribes a more likely than not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken. Under ASC 740, tax positions are evaluated for recognition, derecognition, and measurement using consistent criteria and provide more information about the uncertainty in income tax assets and liabilities. As of June 30, 2017 and 2016, the System does not have an asset or liability recorded for unrecognized tax positions.

UCMC and a substantial number of its subsidiaries are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code (the Code) and is exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The University of Chicago Medicine Care Network, LLC and several entities within CHHD, including Ingalls Captive Insurance, Ltd (ICI), Medcentrix, Inc. (MCX), and Ingalls Provider Group (IPG) are taxable entities under applicable sections of the Code.

Deferred income taxes on taxable entities are recognized for the tax consequences of "temporary differences" by applying enacted statutory tax rates applicable to future years to differences between the consolidated financial statement carrying amounts and the tax bases of existing assets and liabilities. As of June 30, 2017, ICI has a deferred tax asset related to net operating losses (NOL) of \$473, which is recorded within prepaids, inventory, and other current assets in the consolidated balance sheets. As of June 30, 2017, no valuation allowance against the ICI deferred tax assets was considered necessary as management believed that it was more likely than not that the results of future operations would generate sufficient taxable income to realize these deferred tax assets. IPG has an NOL of \$164 at June 30, 2017; however, it has a full valuation allowance as future realization of the NOL is not likely. As of June 30, 2017, MCX has an NOL of \$14,352; however, it has a full valuation allowance as future realization of the NOL is not likely. Income tax benefit for the year ended June 30, 2017 was \$9 and related to ICI. This amount is recorded within supplies and other on the consolidated statement of operations and changes in unrestricted net assets.

#### (u) Reclassifications

Certain 2016 amounts have been reclassified to conform to the 2017 consolidated financial statement presentation, including the reclassification of debt issuance costs from other assets to long-term debt, less current portion of \$7,213 within the 2016 consolidated balance sheet in accordance with the adoption of ASU 2015-13.

## (v) Subsequent Events

The System has performed an evaluation of subsequent events through October 27, 2017, which is the date the consolidated financial statements were issued and other than noted above, there were no other items to disclose.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

# (3) Acquisition

On October 1, 2016, UCMC acquired IHS through an affiliation and member substitution agreement. As a result of this transaction, IHS became a wholly owned subsidiary of UCMC through the newly created CHHD of UCMC. This affiliation positions the System, under the University of Chicago Medicine brand, to expand its integrated academic health delivery system to the South and Southwest Suburbs of Chicago, providing patients access to care at the forefront of medicine where patients live and work.

The affiliation was effected through a member substitution with no consideration paid. For accounting purposes, this transaction is considered an acquisition under ASC Subtopic 958-805, and a contribution was recorded for the fair value of assets, net of liabilities of IHS in the consolidated statement of operations and changes in unrestricted net assets. No goodwill has been recorded as a result of this transaction.

The acquisition-date fair value of identifiable assets and liabilities of IHS at October 1, 2016 consisted of the following:

Fair value of identifiable net assets:	
Cash and cash equivalents	\$ 28,003
Other current assets	58,527
Property and equipment	187,641
Investments	289,888
Other long-term assets	2,720
Restricted assets – investments	9,087
Current liabilities	(82,428)
Long-term debt	(111,990)
Other long-term liabilities	 (58,586)
Contribution of net assets	\$ 322.862

The valuation of the fair value of identifiable assets and liabilities has been completed. In valuing these assets and liabilities, fair values were based on, but not limited to, independent appraisals, discounted cash flows, replacement costs, and actuarially determined values.

Operating expenses for the year ended June 30, 2017 include costs related to the integration of IHS into the System, including support services, operating programs with other health practitioners, as well as costs of valuation and integration consulting.

Operating results and changes in net assets attributable to IHS since the date of acquisition included in the accompanying consolidated statement of operations and changes in net assets for the year ended June 30, 2017 are as follows:

Total operating revenue	\$ 263,549
Excess of revenue over expense	20,195
Change in net assets	1,642

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

The unaudited supplemental pro forma operating results of UCMC as if the IHS affiliation had occurred on July 1, 2015 are as follows:

	 Year ended June 30	
	 2017	2016
	(Unau	idited)
Total operating revenue	\$ 2,092,155	1,960,094
Operating income	76,793	88,329
Excess of revenue over expenses attributable to UCMC		
and affiliates	149,622	75,679

The pro forma information provided should not be construed to be indicative of UCMC's results of operations had the acquisition been consummated on July 1, 2015, and is not intended to project UCMC's results of operations for any future period.

## (4) Agreements and Transactions with the University

The affiliation agreement with the University provides, among other things, that all members of the medical staff will have academic appointments in the University. The affiliation agreement has an initial term of 40 years ending October 1, 2026 unless sooner terminated by mutual consent or as a result of a continuing breach of a material obligation therein or in the operating agreement. The affiliation agreement automatically renews for additional successive 10-year terms following expiration of the initial term, unless either party provides the other with at least two years' prior written notice of its election not to renew.

The operating agreement, as amended, provides, among other things, that the University gives UCMC the right to use and operate certain facilities. The operating agreement is coterminous with the affiliation agreement.

The Lease Agreements provide, among other things, that UCMC will lease from the University certain of the healthcare facilities and land that UCMC operates and occupies. The lease agreements are coterminous with the affiliation agreement.

UCMC purchases various services from the University, including certain employee benefits, utilities, security, telecommunications, and insurance. In addition, certain UCMC accounting records are maintained by the University. During the years ended June 30, 2017 and 2016, the University charged UCMC \$30,014 and \$29,109, respectively, for utilities, security, telecommunications, insurance, and overhead.

The University's Division of Biological Sciences (BSD) provides physician services to UCMC. In 2017 and 2016, UCMC recorded \$229,863 and \$215,727, respectively, in expense related to these services.

UCMC's Board of Trustees adopted a plan of support under which it would provide annual net asset transfers to the University for support of academic programs in biology and medicine. All commitments under this plan are subject to the approval of UCMC's Board of Trustees and do not represent legally binding commitments until that approval. Unpaid portions of commitments approved by the UCMC Board of

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

Trustees are reflected as current liabilities. UCMC recorded net asset transfers of \$71,750 and \$72,025 in 2017 and 2016, respectively, for this support.

# (5) Third-Party Reimbursement Programs

The System follows the provisions of ASU No. 2011-07, *Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities.* ASU No. 2011-07 requires that entities that recognize significant amounts of patient service revenue at the time the services are rendered even though they do not assess the patient's ability to pay must present the provision for bad debts related to patient service revenue as a deduction from patient service revenue (net of contractual allowances and discounts) on their consolidated statements of operations and changes in unrestricted net assets. In addition, there are enhanced disclosures about the entity's policies for recognizing revenue and assessing bad debts. The ASU also requires disclosures of patient service revenue, as well as qualitative and quantitative information about changes in the allowance for doubtful accounts. The provision for doubtful accounts on the accompanying consolidated statements of operations and changes in unrestricted net assets for the years ended June 30, 2017 and 2016 has been presented on a separate line as a deduction from net patient service revenue (net of contractual allowances and discounts) to reflect the application of ASU No. 2011-07.

The System has agreements with third-party payors that provide for reimbursement at amounts different from their established rates. Estimated contractual adjustments arising under third-party reimbursement programs principally represent the differences between the System's billings at list price and the amounts reimbursed by Medicare, Blue Cross, and certain other contracted third-party payors; the difference between the System's billings at list price and the allocated cost of services provided to Medicaid patients; and any differences between estimated third-party reimbursement settlements for prior years and subsequent final settlements. A summary of the reimbursement methodologies with major third-party payors is as follows:

## (a) Medicare

The System is paid for various services rendered to Medicare program beneficiaries under prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic, and other factors. The prospectively determined rates are not subject to retroactive adjustment. The System's classification of patients under the prospective payment systems and the appropriateness of the patients' admissions are subject to validation reviews.

Other services rendered to Medicare beneficiaries are reimbursed based upon a combination of prospectively determined rates and cost reimbursement methodologies. For the cost reimbursement, the System is reimbursed at a tentative rate with final settlement determined after submission of annual cost reports by the System and audits by the Medicare fiscal intermediary. UCMC's Medicare reimbursement reports through June 30, 2012 have been audited by the Medicare fiscal intermediary. CHHD's Medicare reimbursement reports through September 30, 2013 have been audited by the Medicare fiscal intermediary.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

## (b) Medicaid

The System is paid for inpatient acute care services rendered to Medicaid program beneficiaries under prospectively determined rates-per-discharge. For inpatient acute care services, payment rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Medicaid outpatient services are reimbursed based on fee schedules. Medicaid reimbursement methodologies may be subject to periodic adjustment, as well as to changes in existing payment levels and rates, based on the amount of funding available to the State of Illinois Medicaid program and any such changes could have a significant effect on the System's revenue.

## (c) Blue Cross

The System also participates as a provider of healthcare services under reimbursement agreements with Blue Cross under its indemnity program. The provisions of the agreements stipulate that services will be reimbursed at a tentative reimbursement rate and that final reimbursement for these services is determined after the submission of an annual cost report by the System and a review by Blue Cross. UCMC's Blue Cross reimbursement reports for 2016 and prior years have been reviewed by Blue Cross. CHHD's Blue Cross reimbursement reports for 2015 and prior years have been reviewed by Blue Cross.

# (d) Other

The System has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment under these agreements is negotiated by the System and includes prospectively determined rates-per-discharge, discounts from established charges, and prospectively determined per diem rates.

Accruals for settlements with third-party payors are made based on estimates of amounts to be received or paid under the terms of the respective contracts and related settlement principles and regulations of the federal Medicare program, the Illinois Medicaid program, and the Blue Cross Plan of Illinois.

Patients' accounts receivable are reduced by an allowance for uncollectible accounts. In evaluating the collectibility of patients' accounts receivable, the System analyzes its past history and identifies trends for each of its major payor sources of revenue to estimate the appropriate allowance for uncollectible accounts and provision for uncollectible accounts receivable. Management regularly reviews data about these major payor sources of revenue in evaluating the sufficiency of the allowance for uncollectible accounts. For receivables associated with services provided to patients who have third-party coverage, the System analyzes contractually due amounts and provides an allowance for uncollectible accounts and a provision for accounts receivable, if necessary. For receivables associated with patient responsibility (which includes both patients without insurance and patients with deductible and copayment balances due for which third-party coverage exists for part of the bill), the patients are screened against the System's charity care policy. For any remaining patient responsibility balance, the System records a provision for uncollectible accounts receivable in the period of service on the basis of its past experience, which indicates that many patients are unable or unwilling to pay the portion of their bill for which they are financially responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

collected after all reasonable collection efforts have been exhausted is charged off against the allowance for uncollectible accounts.

The System's allowance for uncollectible accounts, which includes uninsured patients, residual copayments, and deductibles for which managed care has already paid, and certain aged Medicaid and Medicaid managed care accounts receivable, increased from 20.4% of accounts receivable at June 30, 2016 to 24.6% of accounts receivable at June 30, 2017. Gross write-offs increased from approximately \$146,200 in fiscal year 2016 to \$210,841 in fiscal year 2017. The System did not have significant write-offs from third-party payors.

Patient service revenue, net of contractual allowances and discounts (but before the provision for uncollectible accounts), recognized in the period from these major payor sources are as follows:

	_	2017	2016
Medicare	\$	493,691	369,511
Medicaid		391,528	272,302
Managed care		1,082,368	911,886
Patients and other		41,972	20,553
Net patient service revenue before provision for			
doubtful accounts	\$_	2,009,559	1,574,252

The System grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors as of June 30, 2017 and 2016 are as follows:

	2017	2016
Medicare	17.7 %	11.1 %
Medicaid	30.0	27.9
Managed care	48.4	60.8
Patients and other	3.9	0.2
	100.0 %	100.0 %

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

A summary of the System's utilization percentages based upon gross patient service revenue is as follows:

	2017	2016
Medicare	38.3 %	37.2 %
Medicaid	23.5	23.7
Managed care	36.5	37.8
Patients and other	1.7	1.3
	100.0 %	100.0 %

# (6) Community Benefits

The following is a summary of the System's unreimbursed cost of providing care, as defined under its Financial Assistance Policy, along with the unreimbursed cost of government sponsored indigent healthcare programs, unreimbursed cost to support education, clinical research, and other community programs for the years ended June 30, 2017 and 2016:

		Year ended June 30	
		2017	2016
Uncompensated care:			
Medicaid sponsored indigent healthcare	\$	72,905	72,619
Medicare sponsored indigent healthcare – cost report		118,486	94,965
Medicare sponsored indigent healthcare – physician services		37,323	11,145
Total uncompensated care		228,714	178,729
Charity care	_	27,199	36,230
	_	255,913	214,959
Unreimbursed education and research:			
Education (Unaudited)		71,044	65,632
Research (Unaudited)		48,000	48,000
Total unreimbursed education and research	_	119,044	113,632
Total community benefits	\$_	374,957	328,591

The System determines the costs associated with providing charity care by aggregating the applicable direct and indirect costs, including salaries, wages and benefits, supplies, and other operating expenses, based on data from its costing system to determine a cost-to-charge ratio. The cost to charge ratio is applied to the charity care charge to calculate the charity care amount reported above. The System amended its financial assistance policies in 2016 to remain in compliance with federal and state regulations.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

## (7) Investments Limited as to Use

The composition of investments limited as to use is as follows at June 30 2017 and 2016:

		201	17		
	Separately	TOID	0.1	<del></del>	2242
	invested	TRIP	Other	Total	2016
Investments carried at fair value:					
Cash equivalents \$	7,544	36,208	2,988	46,740	14,392
Global public equities	128,942	178,813	_	307,755	218,912
Private debt	_	37,896		37,896	33,297
Private equity:					
U.S. venture capital	93,376	38,737	_	132,113	36,382
U.S. corporate finance	_	30,516		30,516	28,994
International	117	44,659	_	44,776	37,351
Real assets:					
Real estate	15,891	45,993	_	61,884	43,056
Natural resources	_	57,826		57,826	42,660
Absolute return:					
Equity oriented	_	76,486		76,486	71,437
Global macro/relative value	_	51,259	_	51,259	47,520
Multistrategy	_	60,244		60,244	53,981
Credit-oriented	_	43,409		43,409	33,928
Protection-oriented	_	14,041	_	14,041	13,036
Fixed income:					
U.S. Treasuries, including TIPS	_	47,810		47,810	28,679
Other fixed income	149,645	6,136	_	155,781	176,433
Beneficial interests in trust	_	_	9,284	9,284	
Funds in trust			45,760	45,760	51,518
Total investments \$	395,515	770,033	58,032	1,223,580	931,576

Investments classified as other consist of construction and debt proceeds to pay interest, donor restricted investments in beneficial interests in trusts, workers' compensation, self-insurance, and trustee-held funds. Investments limited as to use are classified as current assets to the extent they are available to meet current liabilities. Investments are presented in the consolidated financial statements as follows:

	 2017	2016
Current portion of investments limited to use	\$ 20,608	36,768
Investments limited to use, less current portion	 1,202,972	894,808
Total investments limited to use	\$ 1,223,580	931,576

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

A summary of investments limited as to use for the years ended June 30 is as follows:

			2017		
		UCMC	CHHD	Total	2016
Investments limited as to use:					
By the board for capital improvements	/				
restrictions by donors	\$	221,013	194,258	415,271	214,017
Funds held by custodian/trustee					
under indenture agreements		241	2,187	2,428	69
Funds held by trustee for self-insurance	ce	10,444	11,203	21,647	14,749
Collateral for interest rate swap		13,580	620	14,200	36,700
TRIP investments		672,256	97,778	770,034	666,041
Total investments limited					
to use	\$_	917,534	306,046	1,223,580	931,576

The composition of net investment income is as follows for the years ended June 30:

		2017		
	UCMC	CHHD	Total	2016
Interest and dividend income, net \$ Realized gains on sales	11,249	3,142	14,391	11,141
of securities, net Unrealized gains (losses) on	22,694	33,766	56,460	6,451
securities, net	38,613	(20,310)	18,303	(35,951)
\$	72,556	16,598	89,154	(18,359)

Outside of TRIP, UCMC also invests in private equity limited partnerships. As of June 30, 2017, UCMC has commitments of \$1,700 remaining to fund private equity limited partnerships.

#### Fair Value of Financial Instruments

The overall investment objective of the System is to invest its assets in a prudent manner that will achieve a long-term rate of return sufficient to fund a portion of its annual operating activities and increase investment value after inflation. The System diversifies its investments among various asset classes incorporating multiple strategies and external investment managers, including the University Investment Office. Major investment decisions for investments held in TRIP and managed by the University are authorized by the University Board of Trustee's Investment Committee, which oversees the University's investment program in accordance with established guidelines.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

The carrying amount reported in the consolidated statements of financial position for the following approximates fair value because of the short maturities of these instruments: cash and cash equivalents, accounts payable and accrued expenses, and estimated payables under third-party reimbursement programs. Cash equivalent investments include cash equivalents and fixed-income investments, with maturities of less than one year, which are valued based on quoted market prices in active markets. The majority of these investments are held in U.S. money market accounts. Global public equity investments consist of separate accounts, commingled funds with liquidity ranging from daily to monthly, and limited partnerships. Securities held in separate accounts and daily traded commingled funds are generally valued based on quoted market prices in active markets. Commingled funds with monthly liquidity are valued based on independently determined NAV. Limited partnership interests in equity-oriented funds are valued based upon NAV provided by external fund managers.

Investments in private debt, private equity, real estate, and natural resources are in the form of limited partnership interests, which typically invest in private securities for which there is no readily determinable market value. In these cases, market value is determined by external managers based on a combination of discounted cash flow analysis, industry comparables, and outside appraisals. Where private equity, real estate, and natural resources managers hold publicly traded securities, these securities are generally valued based on market prices. The value of the limited partnership interests is held at the manager's reported NAV, unless information becomes available indicating the reported NAV may require adjustment. The methods used by managers to assess the NAV of these external investments vary by asset class. The University's Investment Office monitors the valuation methodologies and practices of managers on behalf of the System.

The absolute return portfolio comprises investments of limited partnership interests in hedge funds and drawdown private equity style partnerships whose managers have the authority to invest in various asset classes at their discretion, including the ability to invest long and short. The majority of the underlying holdings are marketable securities. The remainder of the underlying holdings is held in marketable securities that trade infrequently or in private investments, which are valued by the manager on the basis of an appraised value, discounted cash flow, industry comparables, or some other method. Most hedge funds that hold illiquid investments designate them in special side pockets, which are subject to special restrictions on redemption.

Fixed-income investments consist of directly held actively traded treasuries, separately managed accounts, commingled funds, and bond mutual funds that hold securities, the majority of which have maturities greater than one year. These are valued based on quoted market prices in active markets.

Beneficial interests in trusts represent restricted investments that are assets held by third-party trustees for beneficial interests in perpetual trusts, comprising equities, fixed-income securities, and money market funds.

Funds in trust investments consist primarily of project construction funds and workers' compensation trust funds. Funds in trust comprise 4% cash and cash equivalents, 62% fixed income investments and 34% equity investments at June 30, 2017 and comprised 72% cash and cash equivalents, 16% fixed income investments, and 12% equity investments at June 30, 2016.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

The System believes that the reported amount of its investments is a reasonable estimate of fair value as of June 30, 2017 and 2016. Because of the inherent uncertainties of valuation, these estimated fair values may differ significantly from values that would have been used had a ready market existed. Assets and liabilities recorded at fair value as of June 30, 2017 and 2016 were as follows:

Assets		Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	2017 Total fair value
Cash and cash equivalents	\$	37,446	_	_	37,446
Investments:					
Cash equivalents		46,742	_	_	46,742
Global public equities		130,742	4,470	_	135,212
Private equity – U.S.					
Venture Capital		_	_		_
Real assets:					
Real estate		8,419	_	_	8,419
Natural resources		4,861	_	_	4,861
Absolute return:					
Equity oriented		_	_	_	_
Global macro/relative value		8,312	2,760	_	11,072
Fixed income:					
U.S. Treasuries,					
including TIPS		47,810	_	_	47,810
Other fixed income		119,634	_	_	119,634
Restricted investments		_	_	9,284	9,284
Funds in trust		25,390	20,370	_	45,760
Investments measured at net					
asset value <sup>1</sup>	_				794,786
Total investments at					
fair value		429,356	27,600	9,284	1,261,026
Other assets	_	6,587			6,587
Total assets at					
fair value	\$_	435,943	27,600	9,284	1,267,613
Liabilities	_				
Interest rate swap payable	\$	_	129,450	_	129,450
Total liabilities at	_				
fair value	\$_		129,450		129,450

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

Assets		Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	2016 Total fair value
Cash and cash equivalents	\$	20,335	_	_	20,335
Investments:					
Cash equivalents		14,392	_	_	14,392
Global public equities		96,930	4,104	_	101,034
Real assets:					
Real estate		3,163	_	_	3,163
Absolute return:					
Equity oriented		_	4,702	_	4,702
Global macro/relative value		7,979	2,417	_	10,396
Fixed income:					
U.S. Treasuries, including TIPS		28,679	_	_	28,679
Other fixed income		165,294	_	_	165,294
Funds in trust		51,518	_	_	51,518
Investments measured at net					
asset value <sup>1</sup>	_				552,398
Total investments at fair value		388,290	11,223	_	951,911
Other assets	_	5,850			5,850
Total assets at fair value	\$_	394,140	11,223		957,761
Liabilities	_				
Interest rate swap payables	\$_		165,417		165,417
Total liabilities at fair value	\$_		165,417		165,417

<sup>1</sup> Certain investments that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the balance sheets.

During 2017, there were no transfers between investment Levels 1 and 2 or between Levels 2 and 3. The interest rate swap arrangement has inputs, which can generally be corroborated by market data and is therefore classified within Level 2.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

The following table presents activity for the year ended June 30, 2017 for assets measured at fair value using unobservable inputs classified in Level 3:

	_	Level 3 rollforward
Beginning fair value	\$	
Contribution of CHHD Level 3 net assets		9,087
Change in unrealized gains and losses, net	_	197
Ending fair value	\$_	9,284

In addition, investment securities are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of the System's investments could occur in the next term and that such changes could materially affect the amounts reported in the consolidated financial statements. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the System believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The significant unobservable inputs used in the fair value measurement of the System's long-lived partnership investments include a combination of cost, discounted cash flow analysis, industry comparables, and outside appraisals. Significant changes in any inputs used by investment managers in determining NAVs in isolation would result in a significant changes in fair value measurement.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

The System has made investments in various long-lived partnerships and, in other cases, has entered into contractual agreements that may limit its ability to initiate redemptions due to notice periods, lockups, and gates. Details on typical redemption terms by asset class and type of investment are provided below:

	Remaining life	Redemption terms	Redemption restrictions and terms
Cash	N/A	Daily	None
Global public equities:			
Commingled funds	N/A	Daily to triennial with notice periods of 2 to 180 days	Lock-up provisions for up to 3 years; some investments have a portion of capital held in side pockets with no redemptions permitted
Partnerships	N/A	Monthly to biennial with notice periods of 7 to 90 days	Lock-up provisions for up to 4 years; some investments have a portion of capital held in side pockets with no redemptions permitted
Separate accounts	N/A	Daily with notice periods of 1 to 7 days	Lock-up provisions ranging for up to 1 year
Private debt:			
Drawdown partnerships	1 to 11 years	Redemptions not permitted	N/A
Partnerships	N/A	Redemptions not permitted	Capital held in side pockets with no redemptions permitted
Mutual bond and equity funds	N/A	Daily to monthly with notice periods of 1 to 30 days	None
Real estate funds	N/A	Quarterly with notice periods of 45 to 90 days	None
Funds of funds	N/A	Monthly to quarterly with notice periods of 15 to 185 days	None

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

	Remaining life	Redemption terms	Redemption restrictions and terms
Private equity:			
Drawdown partnerships	1 to 21 years N/A	Redemptions not permitted	N/A None
Separate accounts Partnerships	N/A N/A	Daily with notice period of 1 day Semi-annual with notice period of 90 days	A portion of capital is held in side pockets with no redemptions permitted
Real estate:			
Drawdown partnerships	1 to 16 years	Redemptions not permitted	N/A
Separate accounts	N/A	Daily with notice period of 5 days	None
Natural resources:			
Drawdown partnerships	1 to 17 years	Redemptions not permitted	N/A
Commingled funds	N/A	Daily with notice period of 1 day	None
Absolute return:			
Commingled funds	N/A	Daily to triennial with notice periods of 1 to 122 days	Lock-up provisions for up to 3 years; some investments have a portion of capital held in side pockets with no redemptions permitted
Drawdown partnerships	1 to 4 years	Redemptions not permitted	N/A
Partnerships	N/A	Quarterly to triennial with notice periods of 45 to 180 days	Lock-up provisions for up to 5 years; some investments have a portion of capital held in side pockets with no redemptions permitted
Fixed income:			
Commingled funds	N/A	Weekly to monthly with notice periods of 5 to 10 days	None
Separate accounts	N/A	Daily to monthly with notice periods of 1 to 30 days	None
Funds in trust	N/A	Daily	None

## (8) Endowments

The System's endowment consists of individual donor restricted endowment funds and board-designated endowment funds for a variety of purposes plus the following where the assets have been designated for endowment: pledges receivable, split interest agreements, and other net assets. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. The net assets associated with endowment funds including funds designated by the Board of Trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

Illinois is governed by the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The Board of Trustees of UCMC has interpreted UPMIFA as sustaining the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the System classifies as permanently restricted net assets, (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the System in a manner consistent with the standard of prudence prescribed by UPMIFA.

The System has beneficial interests in trusts. The System has recorded its share of the principal of the trusts as permanently restricted net assets. Distributions from the trusts are recorded within unrestricted net assets if unrestricted; otherwise, they are classified as temporarily restricted net assets until appropriated for expenditure. In some instances the historical costs basis of the funds is not available as the System received the shares in 1929. The fair value of assets associated with individual donor-restricted endowment funds may fall below the amount of the original donation as a result of unfavorable market conditions. There were no such deficiencies at June 30, 2017 and 2016, respectively.

The System has the following donor-restricted endowment activities during the years ended June 30, 2017 and 2016 delineated by net asset class:

	Unrestricted			
	Funds	Temporarily	Permanently	2017
	functioning 1	restricted	restricted	Total
Endowment net assets, beginning of year \$	804,437	67,401	8,112	879,950
Investment return:				
Investment income	29,989	804	197	30,990
Net appreciation (realized and unrealized)	42,567	6,843		49,410
Total investment return	72,556	7,647	197	80,400
Gifts and other additions	_	750	49	799
Contributions – CHHD net assets	_	4,035	9,087	13,122
Appropriation of endowment assets for				
expenditure	(40,953)	(4,997)	_	(45,950)
Appropriation of endowment assets for				
capital	(25,000)	_	_	(25,000)
Other	2,953	371		3,324
Endowment net assets, end of year \$	813,993	75,207	17,445	906,645

<sup>&</sup>lt;sup>1</sup> Funds functioning relate to UCMC only as CHHD does not have such funds at June 30, 2017.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

	Unrestricted Funds functioning	Temporarily restricted	Permanently restricted	2016 Total
Endowment net assets, beginning of year \$	914,479	73,568	8,102	996,149
Investment return: Investment income Net appreciation (realized and unrealized)	16,383 (34,742)	737 (3,162)		17,120 (37,904)
Total investment return	(18,359)	(2,425)	_	(20,784)
Gifts and other additions Appropriation of endowment assets for	_	_	10	10
expenditure Appropriation of endowment assets for	(44,622)	(4,229)	_	(48,851)
capital Other	(50,000) 2,939			(50,000) 3,426
Endowment net assets, end of year \$	804,437	67,401	8,112	879,950

The description of amounts classified as permanently restricted net assets and temporarily restricted net assets (endowments only) as of June 30, 2017 and 2016 is as follows:

		Perpetual	Time- restricted by donor	Time- restricted by law	2017 Total
Restricted for pediatric healthcare Restricted for adult healthcare Restricted for educational and	\$	1,865 11,220		16,143 56,560	18,008 67,780
scientific programs	_	4,360		2,504	6,864
	\$_	17,445		75,207	92,652
	_	Perpetual	Time- restricted by donor	Time- restricted by law	2016 Total
Restricted for pediatric healthcare	<u>-</u> \$	Perpetual 1,865	restricted	restricted	
Restricted for pediatric healthcare Restricted for adult healthcare Restricted for educational and scientific programs	<u>-</u> \$	•	restricted	restricted by law	Total

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

## Investment and Spending Policies

The System has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. The System expects its endowment funds to provide an average rate of return of approximately 6% annually. To achieve its long-term rate of return objectives, the System relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). Actual returns in any given year may vary from this amount.

For endowments invested in TRIP, the Board of Trustees of the System has adopted the University's method to be used to appropriate endowment funds for expenditure, including following the University's payout formula. The University utilizes the total return concept in allocating endowment income. In accordance with the University's total return objective, between 4.5% and 5.5% of a 12-quarter moving average of the fair value of endowment investments, lagged by one year, is available each year for expenditure in the form of endowment payout. The exact payout percentage, which is set each year by the Board of Trustees with the objective of a 5% average payout over time, was 5.5% for the fiscal years ended June 30, 2017 and 2016. If endowment income received is not sufficient to support the total return objective, the balance is provided from capital gains. If income received is in excess of the objective, the balance is reinvested in the endowment.

For endowments invested apart from TRIP, the System calculates a payout of 4% annually on a rolling 24-month average market value. In establishing this policy, the Board considered the expected long term rate of return on its endowment.

## (9) Property, Plant, and Equipment

The components of property, plant, and equipment as of June 30 are as follows:

		2017	2016
Land and land rights	\$	54,505	36,008
Buildings and improvements		1,765,121	1,417,450
Equipment		667,388	524,676
Construction in progress		38,456	197,346
		2,525,470	2,175,480
Less accumulated depreciation	_	(900,265)	(795,348)
Total property, plant, and equipment, net	\$	1,625,205	1,380,132

UCMC's net property, plant, and equipment cost includes \$8,700 and \$9,200 at June 30, 2017 and 2016 representing assets under capital leases with the University. The cost of buildings that are jointly used by the University and UCMC is allocated based on the lease provisions. In addition, land and land rights include \$22,500 and \$15,000 for 2017 and 2016, respectively, which represents the unamortized portion of initial lease payments made to the University.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

A new ambulatory center in Orland Park and the build out for the Center for Care and Discovery third and fourth floors were placed into service in 2017. Capitalized interest costs in 2017 and 2016 were approximately \$2,800 and \$3,200, respectively. Construction in progress consists primarily of a new Adult Emergency Department and Trauma Center scheduled to open in 2018 and various other renovation projects. As of June 30, 2017, the System had total contractual commitments associated with ongoing capital projects of approximately \$181,700.

## (10) Long-Term Debt

The UCMC Obligated Group's long-term debt is issued pursuant to the UCMC Amended and Restated Master Trust Indenture (MTI) dated as of November 1, 1998, as subsequently amended and supplemented. UCMC is the only member of the Obligated Group. UCM Care Network, Title Holding Corporation, and CHHD are not members of the UCMC Obligated Group. Each series of bonds is collateralized by the unrestricted receivables of UCMC and subject to certain restrictions under the Master Trust Indenture.

The CHHD Obligated Group's long-term debt is issued pursuant to the CHHD Amended and Restated Master Trust Indenture dated as of October 15, 1995. The CHHD Obligated Group consists of CHHD, Ingalls Memorial Hospital, Ingalls Home Care, and Ingalls Development Foundation.

Long-term debt at June 30, 2017 and 2016 consists of the following:

	Fiscal year			
	maturity	Interest rate	2017	2016
University of Chicago Medical Center:				
Fixed rate:				
Illinois Finance Authority:				
Series 2009A and 2009B, 2009B partially legally defeased in 2017	2027	5.0 % \$	105,160	138,915
Series 2009C, legally defeased in 2017	2037	4.7	_	60,900
Series 2009D1 and 2009D2 (Synthetically fixed rate)	2044	3.9	70,000	70,000
Series 2009E1 and 2009E2 (Synthetically fixed rate)	2044	3.9	70,000	70,000
Series 2010A and 2010B (Synthetically fixed rate)	2045	3.9	92,500	92,500
Series 2011A and 2011B (Synthetically fixed rate)	2045	3.9	92,500	92,500
Series 2011C, legally defeased in 2017	2042	5.5	_	90,000
Series 2012A	2037	4.7	64,615	66,565
Series 2015A	2029	5.0	21,895	21,895
Series 2016A	2027	5.0	22,830	_
Series 2016B	2042	5.0	164,490	_
Teachers Insurance and Annuity Association of America (TIAA)				
Series 2017A	2047	4.4	30,000	_
Unamortized premium			28,412	10,804
Total fixed rate			762,402	714,079
Variable rate:				
Series 2013A	2020	1.3	72,477	73,757
Illinois Educational Facilities Authority (IEFA)	2038	0.7	72,567	75,671
Total variable rate			145,044	149,428
Unamortized debt issuance costs			(7,108)	(7,213)
Less current portion of long-term debt			(13,868)	(13,255)
Total UCMC long-term portion of debt, less current portion		\$	886,470	843,039

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

	Fiscal year maturity	Interest rate	2017	2016
UCMC Title Holding Corporation:				
Fixed rate:				
Brownfield Revitalization 40 – Promissory note A	2024	1.5 % \$	4,850	_
Urban Development Fund XLVI – Promissory note A	2024	1.5	4,850	_
Urban Development Fund LI – Promissory note A	2024	1.8	6,500	_
Citi NMTC – QLICI	2032	1.2	3,476	_
Citi NMTC – QLICI	2032	1.2	1,620	
Total UCMC Title Holding Corporation debt		\$	21,296	
Community Health and Hospital Division:				
Fixed Rate: Series 2013	2043	3.5-5.0% \$	61,565	_
Variable Rate: Series 2004	2034	Varies	43,925	_
Revolving credit agreement		LIBOR + 1.25%	3,000	_
Unamortized debt fair value adjustment as part of acquisition			4,739	_
Unamortized debt issuance costs			(618)	
Total debt and unamortized premiums (discount)			112,611	_
Less current portion of long-term debt			(5,550)	
Total CHHD debt, excluding current portion		\$	107,061	
Total notes and bonds payable:				
Less current portion		\$	1,034,245	863,507
Long-term debt, excluding current portion			(19,418)	(13,225)
		\$	1,014,827	850,282

Scheduled annual repayments for the next five years and thereafter are as follows at June 30:

	 Amount	
Year:		
2018	\$ 19,418	
2019	17,183	
2020	18,003	
2021	18,875	
2022	19,788	
Thereafter	 940,978	
	\$ 1,034,245	

# **UCMC Obligated Group**

Under its various credit agreements, UCMC is subject to certain financial covenants, including maintaining a minimum debt service coverage ratio; maintaining minimum levels of days' cash on hand; maintaining debt to capitalization at certain levels; limitations on selling, leasing, or otherwise, disposing of UCMC property; and certain other nonfinancial covenants.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

## Recent Financing Activity

In November 2016, the Illinois Finance Authority issued \$22,830 and \$164,490 of Series 2016A and Series 2016B Revenue Refunding Bonds, respectively, allocated to UCMC with Series 2016A bonds refunding a portion of the 2009B bonds and the Series 2016B bonds refunding all of Series 2009C and Series 2011C bonds via a legal defeasance. The Series 2016A and 2016B bonds are secured by a Direct Note Obligation, and were issued pursuant to the Master Trust Indenture. The extinguishment of the Series 2009C and 2011C bonds resulted in a loss on extinguishment of debt of \$27,028 recorded as a nonoperating loss in 2017 within the consolidated statements of operations and changes in unrestricted net assets.

In February 2017, UCMC secured a taxable private placement loan through the Teachers Insurance and Annuity Association of America (TIAA) in the amount of \$30,000 with interest fixed at 4.4% annually. The proceeds from the financing are utilized for projects, such as the relocation of the adult emergency department, the addition of an adult trauma center, and other capital projects at the medical center campus.

During 2017, UCMC entered into New Market Tax Credit (NMTC) financing agreements with various entities for the purposes of financing various projects at UCMC that would benefit the surrounding community. The NMTC program was established in 2000 by the United States Congress and is administered by the Department of Treasury to encourage private investment in qualifying low-income communities. Pursuant to Section 45(D) of the Internal Revenue Code, UCMC's NMTC structure consists of an NMTC investor (Investor) who provided qualified equity investments to a community development entity (CDE) who in turn provided debt financing to a separate not for profit tax exempt entity, which is a qualified active low income community business (QALICB).

In July 2016, UCMC was a lender in the NMTC structure for the financing of certain equipment. Because UCMC has the power to appoint all board members of UCMC Title Holding Corporation, the QALICB has been consolidated in the financial statements. The Investor made qualifying equity investments into various CDE funds, including Twain Investment Fund 177, LLC and USBCDC Investment Fund 147, LLC (the CDE Funds), which in turn provided debt financing of \$16,200 to UCMC Title Holding Corporation to fund qualified costs of equipment, as required under the terms of the agreement. Management anticipates that the NMTC structure will stay in effect through July 2023 when the NMTC tax compliance period expires. At that time, management believes the Investor will exercise its Put Option in the Put and Call Agreement, allowing UCMC to acquire a 100% equity interest in the investment fund for \$1. If the Put Option is not exercised, UCMC has the right to call for the purchase of a 100% equity interest in the investment fund at a fair market value. In either case, once the option is exercised, UCMC's loan to the Investment Fund would be extinguished, the investment fund and the CDE Funds would be dissolved, and the loans from the CDE Funds to UCMC Title Holding Corporation would be extinguished.

In June 2017, UCMC was a lender in the NMTC structure for the construction of a new emergency department and adult trauma center. Because UCMC has the power to appoint all board members of UCMC Title Holding Corporation II NFP, the QALICB has been consolidated in the financial statements. The Investor made qualifying equity investments into various CDE funds, including UCMC Trauma Center NMTC Investment Fund, LLC (the CDE Funds), which in turn provided debt financing of \$5,096 to UCMC Title Holding Corporation to fund qualified construction costs and equipment, as required under the terms

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

of the agreement. Management anticipates that the NMTC structure will stay in effect through July 2024 when the NMTC tax compliance period expires. At that time, management believes the Investor will exercise its Put Option in the Put and Call Agreement, allowing UCMC to acquire a 100% equity interest in the investment fund for \$5. If the Put Option is not exercised, UCMC has the right to call for the purchase of a 100% equity interest in the investment fund at a fair market value. In either case, once the option is exercised, UCMC's loan to the investment fund would be extinguished, the investment fund and the CDE Funds would be dissolved, and the loans from the CDE Funds to UCMC Title Holding Corporation II NFP would be extinguished.

# Letters of Credit

Payment on each of the variable rate demand revenue bonds is also collateralized by a letter of credit. The letter of credit that supports the Series 2009D bonds expires in June 2019. The letter of credit that supports the 2009E bonds expires in December 2018. The letters of credit that support the Series 2010A and Series 2010B bonds expire in November 2020 and November 2018, respectively, and the letters of credit that support the Series 2011A and Series 2011B bonds expire in May 2021. The letters of credit are subject to certain restrictions, which include financial ratio requirements and consent to future indebtedness. The most restrictive financial ratio is to maintain a debt service coverage ratio of 1:25:1. Payment on each of the IEFA bonds is collateralized by a letter of credit maturing November 2019. The letter of credit is subject to certain restrictions, which include financial ratio requirements. The most restrictive financial ratio is to maintain a debt service coverage ratio of 1.75:1. UCMC was in compliance with all applicable debt covenants at June 30, 2017.

Included in UCMC's debt is \$72,567 of commercial paper revenue notes and \$325,000 of variable rate demand bonds. In the event that UCMC's remarketing agents are unable to remarket the bonds, the trustee of the bonds will tender them under the letters of credit. Scheduled repayments under the letters of credit are between one and three years, beginning after a grace period of at least one year from the event, and bear interest rates different from those associated with the original bond issue. Any bonds tendered are still eligible to be remarketed. Bonds subsequently remarketed would be subject to the original bond repayment schedules.

## **Community Health and Hospital Division**

The Series 2004 Variable Rate Revenue Bonds bear interest at a weekly rate. Holders of the Series 2004 Variable Rate Demand Revenue Bonds have a put option that allows them to require redemptions of the bonds prior to maturity. CHHD Obligated Group has an agreement with an underwriter to remarket any bonds redeemed based on the exercise of put options. The Series 2004 Variable Rate Demand Revenue Bonds are collateralized by a letter of credit, which expires on July 3, 2018, and liquidity facility agreement, as well as a financial guaranty insurance policy. In the event the bank does not renew the letter of credit and a substitute letter of credit is not secured, the Series 2004 bonds would be subject to acceleration. Any liquidity advances as a result of failed remarketing are repayable to the bank commencing 367 days after the liquidity drawing date and continue every quarter thereafter with the outstanding portion of the liquidity advance fully paid on the fifth anniversary of the liquidity drawing date. The Series 2004 bonds have been classified as long-term debt in the accompanying 2016 and 2015 consolidated balance sheets in accordance with the terms of the letter of credit and liquidity facility agreement. The effective interest rate on the Series 2004 bonds was 0.55% for 2017.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

On January 17, 2013, CHHD issued fixed rate revenue bonds, Series 2013, in the amount of \$61,860 through the IFA. The Series 2013 bonds were issued pursuant to the MTI and are subject to mandatory, optional, and extraordinary redemption prior to maturity and mandatory tender. Mandatory redemption or payment at maturity will occur, without premium, on May 15 of each year, beginning in 2017 and continuing through 2043. The Series 2013 obligation will be equally and ratably secured by a security interest in the unrestricted receivables of the members of the CHHD Obligated Group.

UCMC has a \$100,000 line of credit from a commercial bank, which expires September 28, 2017. As of June 30, 2017 and 2016, no amount was outstanding under this line. CHHD has a revolving credit agreement of \$10,000, which expires on October 31, 2018. As of June 30, 2017, there was \$3,000 of outstanding borrowings under this agreement. Interest is paid on draws at LIBOR + 1.25%, which was 2.26% as of June 30, 2017. The effective interest rate for the year ended June 30, 2017 was 2.26%.

#### Other Debt Related Items

Scheduled principal repayments on long-term debt based on the variable rate demand notes being put back to the System and a corresponding draw being made on the underlying credit facility, if available, are as follows:

Year ending June 30:		
2018	\$	27,885
2019		150,044
2020		168,140
2021		147,575
2022		31,640
Thereafter	_	508,961
	\$_	1,034,245

The System paid interest, net of capitalized interest, of approximately \$32,170 and \$32,700 in 2017 and 2016, respectively.

## (11) Derivative Instruments

The System has interest rate related derivative instruments to manage its exposure on debt instruments. By using derivative financial instruments to manage the risk of changes in interest rates, the System exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contracts. When the fair value of a derivative contract is positive, the counterparty owes the System, which creates credit risk for the System. When the fair value of a derivative contract is negative, the System owes the counterparty, and therefore, it does not possess credit risk; however, the System is required to post collateral to the counterparty when certain thresholds as defined in the derivative agreements are met. Market risk is the adverse effect on the value of a financial instrument that results from a change in interest rates. The market risk associated with interest rate changes is managed by establishing and monitoring parameters that limit the types and degree of market risk that may

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

be undertaken. System management also mitigates risk through periodic reviews of their derivative positions in the context of their total blended cost of capital.

The System is required to post collateral under the specific terms and conditions for the various interest rate swap agreements as described below. At June 30, 2017 and 2016, \$14,200 and \$36,700 was held as collateral, respectively, and recorded in current portion of investments limited to use. Collateral postings are primarily driven by the value of the swap as measured at the reset date. Collateral requirements increase if credit ratings were to be downgraded.

University of Chicago Medical Center Interest Rate Swap Agreement

In August 2006, UCMC entered into a forward starting swap transaction against contemplated variable rate borrowing for the Center for Care and Discovery. This is a cash flow hedge against interest on the variable rate debt. The fair value of these swap agreements is the estimated amount that UCMC would have to pay or receive to terminate the agreements as of the consolidated balance sheet date, taking into account current interest rates and the current creditworthiness of the swap counterparty. The swap values are based on the London Interbank Rate (LIBOR). The inputs to the fair value estimate are considered Level 2 in the fair value hierarchy. The effective date of the swap was August 2011. In July 2011, UCMC novated the original swap agreement to divide the original notional amount in two equal parts between financial institutions. The fair value of the terminated portion of the hedge on the date of the novation was recorded in net assets in the amount of \$35,123 and is being amortized into interest expense over the life of the related debt, commencing on February 23, 2013, the date the Center for Care and Discovery was placed into service. The new agreement is being accounted for as a hedge. The combined notional amount of the swap is \$325,000 and the effective start date was August 2011. Management has determined that the interest rate swaps are effective, and have qualified for hedge accounting. Management has recognized ineffectiveness of approximately \$2,095 in 2017 and an ineffectiveness of \$(2,506) in 2016. This movement reflects the spread between tax-exempt interest rates and LIBOR during the period. The effective portion of these swaps is included in other changes in unrestricted net assets. The interest rate swaps terminate on February 1, 2044. Cash settlement payments related to the swaps were accumulated in net assets while the Center for Care and Discovery was under construction, and are being amortized into depreciation expense over the life of the building. Amortization commenced on February 23, 2013, the date the Center for Care and Discovery was placed into service. Cash settlement payments after the Center for Care and Discovery was placed into service are recorded in interest expense.

The following summarizes the general terms of each of UCMC's swap agreements:

Effective date	Associated debt series	Original term	Current notional amount	UCMC pays	UCMC receives
August 9, 2011	2009 D/E, 2010				
-	A/B, 2011 A/B	32.5 Years	\$ 162,500,000	3.89 %	68% of LIBOR
August 9, 2011	2009 D/E, 2010				
-	A/B, 2011 A/B	32.5 Years	162,500,000	3.97	68% of LIBOR

The fair value of each swap is the estimated amount UCMC would receive or pay to terminate the swap agreement at the reporting date, taking into account current interest rates and the current creditworthiness

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

of the swap counterparties. The fair value is included in interest rate swap liability on the consolidated balance sheets, while the change in fair value is recorded in unrestricted net assets for the effective portion of the change and in nonoperating gains and losses for the ineffective portion of the change.

Community Health and Hospital Division

# (a) 2004 Interest Rate Swap Agreement

IMH entered into an interest rate swap agreement on June 28, 2004 to lock in long-term fixed rates on the Series 2004 variable-rate debt issuance, with a notional amount of \$48,000 and a maturity date of May 15, 2034. Under the agreement, IMH receives, on a monthly basis, payments at the weekly Securities Industry Financial Market Association (SIFMA) rate. In exchange for this indexed payment received, IMH pays, on a monthly basis, an annualized fixed rate of 4.61% This agreement was amended on March 1, 2013 to include the 2004 basis swap agreement. Under the amended agreement, the notional amount and maturity did not change, and IMH receives, on a monthly basis, 67.00% of one-month LIBOR plus 47.5 basis points and makes payments on a monthly basis, an annualized fixed rate of 4.61%.

The swap is not designated as a hedging instrument, and therefore, the change in fair value of the 2004 interest rate swap agreement was recognized as a component of change in fair value of nonhedged derivative instruments in the accompanying consolidated statements of operations and changes in unrestricted in net assets. The fair value of the Series 2004 interest rate swap agreement liability of \$9,575 at June 30, 2017 is included as a component of other long-term liabilities in the accompanying consolidated balance sheets. The change in the fair value of the Series 2004 interest rate swap agreement of \$(3,575) in 2017 has been included as a component of change in fair value of nonhedged derivative instruments. The differential to be paid or received under the Series 2004 interest rate swap agreement is recognized monthly and amounted to \$(1,253) of net payments during 2017, which have been included as a component of interest and amortization expense in the accompanying consolidated statement of operations and changes in unrestricted net assets.

## (b) CMS Basis Swap Agreement

On April 6, 2005, IMH entered into an interest rate swap agreement on the Series 1994, Series 1985B, and Series 1985C debt (Basis Swaps). IMH amended the Basis Swaps on July 13, 2006. The Basis Swaps have a notional amount of \$67,835 whereby IMH will receive, on a quarterly basis, 71.75% of one-month LIBOR and make payments at the weekly SIFMA rate until May 14, 2024. The fair value of the Basis Swaps receivable of \$283 has been included as a component of other long-term liabilities in the accompanying 2017 consolidated balance sheets, respectively. The Basis Swaps are not designated as a hedging instrument, and therefore, the change in fair value of the Basis Swaps is included as a component of change in fair value of nonhedged derivative instruments in the amount of \$(14) in the accompanying 2017 consolidated statements of operations and changes in unrestricted net assets. The differential to be paid or received under the Basis Swaps is recognized monthly and amounted to \$240 of net receipts, which have been included as a reduction of \$240 of interest and amortization expense and an increase of \$0 in change in fair value of nonhedged derivative instruments in the accompanying 2017 consolidated statement of operations and changes in unrestricted net assets.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

A summary of outstanding positions under the interest rate swap agreements for CHHD at June 30, 2017 is as follows:

Series	 Notional amount	Maturity date	Rate received	Rate paid
2004 Interest rate swap agreement: 2004	\$ 28,460	May 15, 2034*	% of LIBOR ***	Fixed 4.61%
CMS basis swap agreement	43,925	May 15, 2024	% of LIBOR**	SIFMA

<sup>\*</sup> Maturity date listed is final maturity date of Series 2004 debt, as notional amounts correspond directly to scheduled debt repayment of the underlying debt.

# (12) Commitments

#### Leases

The System leases office space and equipment under leases that are classified as operating leases. Future minimum payments required under noncancelable leases as of June 30 are as follows:

	 Operating		Capital
2018	\$ 5,356		1,492
2019	5,230		1,293
2020	5,142		788
2021	2,546		774
2022 and thereafter	 20,812		14,749
	\$ 39,086	=	19,096
Less amount representing interest			8,904
Present value of net minimum capital lease			
payments		\$	10,192

The amount of total assets capitalized under these leases at both June 30, 2017 and June 30, 2016 is \$11,405 and \$0 with related accumulated depreciation of \$714 and \$0, respectively. Rental expense was approximately \$7,700 and \$6,100 for the years ended June 30, 2017 and 2016, respectively.

<sup>\*\*</sup> Rate received is 71.75% of one-month LIBOR.

<sup>\*\*\*</sup> Rate received is 67.00% of one-month LIBOR plus 47.5 basis points.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

# (13) Insurance

Professional and General Liability

The System maintains separate self-insurance programs for UCMC and CHHD. UCMC is included under certain of the University's insurance programs. Since 1977, UCMC, in conjunction with the University, has maintained a self-insurance program for its medical malpractice liability. This program is supplemented with commercial excess insurance above the University's self-insurance retention, which for the years ended June 30, 2017 and 2016 was \$5,000 per claim and unlimited in the aggregate. Claims in excess of \$5,000 are subject to an additional self-insurance retention limited to \$12,500 per claim and \$22,500 in aggregate. There are no assurances that the University will be able to renew existing policies or procure coverage on similar terms in the future.

CHHD maintains a self-insurance program for professional and general liability. Coverage from commercial insurance carriers is maintained for claims in excess of self-insured retentions at various levels by policy year. CHHD established a trust fund with an independent trustee for the administration of assets funded under the malpractice and general liability self-insurance program.

The System has engaged professional consultants for calculating an estimated liability for medical malpractice self-insurance and is actuarially determined based upon estimated claim reserves and various assumptions, and represents the estimated present value of self-insurance claims that will be settled in the future. It considers anticipated payout patterns, as well as interest to be earned on available assets prior to payment. The discount rate used to value the self-insurance liability is a rate commensurate with the duration of anticipated payments.

A comparison of the estimated liability for incurred malpractice claims (filed and not filed) and assets available for claims for the combined University and UCMC self-insurance program as of June 30, 2017 and 2016 is presented below:

	2017	2016
Actuarial present value of self-insurance liability for medical		
malpractice	\$ 236,770	238,213
Total assets available for claims	297,788	300,352

If the present-value method were not used, the ultimate liability for medical malpractice self-insurance claims would be approximately \$34,000 higher at June 30, 2017. The interest rate assumed in determining the present value was 3.75% and 3.50% for 2017 and 2016, respectively. UCMC has recorded its pro-rata share of the malpractice self-insurance liability in the amount of \$120,939 and \$117,410 at June 30, 2017 and June 30, 2016, respectively, with an offsetting receivable from the malpractice trust to cover any related claims. The malpractice self-insurance trust assets consist primarily of funds held in TRIP.

UCMC recognizes as malpractice expense its negotiated pro-rata share of the actuarially determined normal contribution, with gains and losses amortized over five years, with no retroactive adjustments, as provided in the operating agreement. For fiscal year 2018, UCMC's expense is estimated to be approximately \$7,900 related to malpractice insurance.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

CHHD estimated the total liability for self-insured malpractice and general claims at \$33,223 at June 30, 2017. Accruals for CHHD professional and general liabilities are recorded on an undiscounted basis.

# (14) Pension Plans

Active Plans

A majority of UCMC's personnel participate in the University's defined benefit and contribution pension plans, which are considered multi-employer pension plans. Under the defined benefit portion of this plan, benefits are based on years of service and the employee's compensation for the five highest paid consecutive years within the last ten years of employment. UCMC and the University make annual contributions to this portion of the plan at a rate necessary to maintain plan funding based on the guidelines set forth by the Employee Retirement Income Security Act of 1974, on an actuarially determined basis. UCMC recognizes its share of net periodic pension cost as expense and any difference in the contribution amount as a transfer of unrestricted net assets. The adjustment to net assets was \$2,266 and \$(4,429) for the years ended June 30, 2017 and 2016. Contributions of \$0 and \$32,500 were made in the fiscal years ended June 30, 2017 and 2016. UCMC expects to make contributions not to exceed \$10,000 for the fiscal year ending June 30, 2018.

Effective January 1, 2017, the 401(a) defined benefit pension plan was frozen for UCMC employees participating in the plan and was replaced with an enhanced defined contribution plan. This curtailment resulted in a current year reduction in the defined benefit pension obligation and a curtailment credit, whereas UCMC's expense for the plans was \$12,650 for the year ended June 30, 2017. Under the defined contribution portion of the plan, UCMC and plan participants make contributions that accrue to the benefit of the participants at retirement. UCMC's contributions, which are based on a percentage of each covered employee's salary, totaled approximately \$16,400 and \$7,800 for the years ended June 30, 2017 and 2016, respectively.

UCMC's expense related the multiemployer University's defined benefit plans included in the University's financial statements for the years ended June 30, 2017 and 2016 is as follows:

		Contribution	n of UCMC
Plan name	EIN	2017	2016
University of Chicago Retirement Income	26 2477420 002 ¢		4.000
Plan for Employees University of Chicago Pension Plan for	36-2177139-002 \$	_	4,000
Staff Employees	36-2177139-003		28,500
	\$		32,500

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

The benefit obligation, fair value of plan assets, and funded status for the University's defined benefit plan included in the University's financial statements as of June 30 are shown below.

	 2017	2016
Projected benefit obligation	\$ 967,817	1,017,137
Fair value of plan assets	 772,032	741,696
Deficit of plan assets over benefit obligation	\$ (195,785)	(275,441)

The weighted average assumptions used in the accounting for the plan are shown below.

	2017	2016	
Discount rate	3.7 %	3.6 %	
Expected return on plan assets	6.5	6.5	
Rate of compensation increase	3.5	3.5	

The weighted average asset allocation for the plan is as follows:

	2017	2016
Domestic equities	26 %	26 %
International equity	21	20
Fixed income	53	54
	100 %_	100 %

The pension and other postretirement benefit obligation considers anticipated payout patterns as well as investment returns on available assets prior to payment. The discount rate used to value the pension and other postretirement benefit obligation is a risk-adjusted rate commensurate with the duration of anticipated payments. These inputs to the fair value estimate are considered Level 2 in the fair value hierarchy.

Expected future benefit payments excluding plan expenses are as follows:

Fiscal year:	
2018	\$ 102,597
2019	60,777
2020	58,878
2021	59,278
2022	58,876
2023-2027	267,576

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

UCMC and CHHD also maintain additional defined contribution retirement plans for employees. The System's pension expense under these distinct defined contribution retirement plans was \$8,200 and \$5,300 for the years ended June 30, 2017 and 2016, respectively.

# Curtailed and Frozen Plan

In June 2002, UCMC assumed sponsorship of the Louis A. Weiss Memorial Hospital Pension Plan (Employer Identification Number 36-3488183, Plan Number 003), which covers employees of a former affiliate. Participation and benefit accruals are frozen. All benefit accruals are fully vested.

Components of net periodic pension cost and other amounts recognized in unrestricted net assets include the following:

		Year ended June 30		
		2017	2016	
Net periodic pension cost:				
Service cost	\$_			
Net periodic pension cost	\$_	<u> </u>		
Other changes in plan assets and benefit obligations recognized in unrestricted net assets:				
Interest cost	\$	2,155	2,513	
Expected return on plan assets		(2,976)	(3,009)	
Amortization of unrecognized net actuarial loss		1,181	926	
Liability for pension benefits	_	2,918	(4,429)	
Total recognized in net periodic pension cost and				
unrestricted net assets	\$_	(2,558)	4,859	

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

The following table sets forth additional required pension disclosure information for this plan:

	 Year ended June 30		
	2017	2016	
Changes in projected benefit obligation:			
Benefit obligation at beginning of year	\$ 63,511	60,318	
Interest cost	2,155	2,513	
Net actuarial loss (gain)	(1,001)	4,236	
Benefits paid	 (3,560)	(3,556)	
	 61,105	63,511	
Changes in plan assets:			
Fair value of plan assets at beginning of year	50,371	52,037	
Actual return on plan assets	3,711	1,890	
Employer contribution	_	_	
Benefits paid	 (3,560)	(3,556)	
	 50,522	50,371	
Funded status at end of year	\$ (10,583)	(13,140)	

Amounts recognized in the consolidated balance sheets are included in noncurrent liabilities.

Accumulated plan benefits equal projected plan benefits. Assumptions used in the accounting for the net periodic pension cost were as follows:

	2017	2016
Discount rate	3.7 %	3.5 %
Expected return on plan assets	6.0	6.0
Rate of compensation increase	N/A	N/A
Weighted average asset allocations for plan assets are as follows:		
	2017	2016
Cash	1 %	3 %
Fixed income	60	60
Domestic equities	27	27
International equities	12	10
•	<del></del>	

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

All plan assets are valued using Level 1 inputs in 2017 and 2016. The target asset allocation is 40% equities and 60% fixed income. The expected return on plan assets is based on historical investment returns for similar investment portfolios.

UCMC expects to make contributions of \$3,000 to the plan in the fiscal year ended June 30, 2017.

Expected future benefit payments are as follows:

Fiscal year:	
2018	\$ 4,011
2019	3,985
2020	4,000
2021	3,962
2022	3,958
2023–2027	19,496

# (15) Pledges

Pledges receivable at June 30 are comprised of:

	 2017	2016
Unconditional promises expected to be collected in:		
Less than one year	\$ 1,256	1,661
One year to five years	2,440	2,602
More than five years	 	
	3,696	4,263
Less unamortized discount (discount rate 4.14%)	 (77)	(113)
Total	\$ 3,619	4,150

# (16) Restricted Net Assets

Temporarily restricted net assets are available for the following purposes as of June 30:

	 2017		
Pediatric healthcare	\$ 20,220	18,064	
Adult healthcare	57,890	52,285	
Educational and scientific programs	6,071	5,254	
Capital and other purposes	 6,280	6,322	
Total	\$ 90,461	81,925	

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

Income from permanently restricted net assets is restricted for:

	 2017	2016
Pediatric healthcare	\$ 3,941	1,865
Adult healthcare	4,287	1,935
Educational and scientific programs	 9,217	4,312
Total	\$ 17,445	8,112

## (17) Functional Expenses

Total operating expenses by function are as follows for the years ended June 30:

		2017	2016
Healthcare services	\$	1,765,085	1,403,939
General and administrative		158,001	106,256
Total	\$_	1,923,086	1,510,195

## (18) Contingencies

The System is subject to complaints, claims, and litigation, which have risen in the normal course of business. In addition, the System is subject to reviews by various federal and state government agencies to assure compliance with applicable laws, some of which are subject to different interpretations. While the outcome of these suits cannot be determined at this time, management, based on advice from legal counsel, believes that any loss that may arise from these actions will not have a material adverse effect on the financial position or results of operations of the System.

# (a) Medicare and Medicaid Reimbursement

For the year ended June 30, 2017, the System recognized approximately 24.6% of net patient service revenue from services provided to Medicare beneficiaries. Recently enacted healthcare reform and other Medicare legislation may have an adverse effect on UCMC's net patient service revenue. Medicaid-payment methodologies and rates may be subject to modification based on the amount of funding available to the State of Illinois Medicaid Program.

The System has received and expects to receive future notices from the Medicare program requiring that they provide Medicare with documentation for claims to carry out the Recovery Audit Contract (RAC) program. The System is responding to these requests. Review of claims through the RAC program may result in a liability to the Medicare program and could have an adverse impact on the System's net patient service revenue.

Notes to Consolidated Financial Statements

June 30, 2017 and 2016

(Dollars in thousands)

## (b) The Patient Protection and Affordable Care Act and Other Enacted Legislation

In March 2010, the Patient Protection and Affordable Care Act of 2010 (the Affordable Care Act) was enacted. Some of the provisions of the Affordable Care Act took effect immediately, while others will take effect or will be phased in over time, ranging from a few months to ten years following approval. The Affordable Care Act was designed to make available, or subsidize the premium costs of, healthcare insurance for some of the millions of currently uninsured or underinsured consumers below certain income levels. An increase in utilization of healthcare services by those who are currently avoiding or rationing their healthcare was expected. Although bad debt expenses and/or charity care provided were expected to be reduced, increased utilization would be associated with increased variable and fixed costs of providing healthcare services, which may or may not be offset by increased revenue.

The Affordable Care Act contains more than 32 sections related to healthcare fraud and abuse and program integrity. The potential for increased legal exposure related to the Affordable Care Act's enhanced compliance and regulatory requirements could increase operating expenses.

The System continues to analyze the Affordable Care Act to assess its effects on current and projected operations, financial performance, and financial condition.

# (c) Regulatory Investigations

The U.S. Department of Justice and other federal agencies routinely conduct regulatory investigations and compliance audits of healthcare providers. The System is subject to these regulatory efforts. Additionally, the laws and regulations governing the Medicare, Medicaid, and other government healthcare programs are extremely complex and subject to interpretation, making compliance an ongoing challenge for The System and other healthcare organizations. Recently the federal government has increased its enforcement activity, including audits and investigations related to billing practices, clinical documentation, and related matters. The System maintains a compliance program and conducts audits and other activities to identify potential compliance issues, including overpayments to governmental payors.

## (d) Tax Exemption for Sales Tax and Property Tax

Effective June 14, 2012, the Governor of Illinois signed into law, Public Act 97-0688, which creates new standards for state income tax and property tax exemptions in Illinois. The law establishes new standards for the issuance of charitable exemptions, including requirements for a nonprofit hospital to certify annually that in the prior year, it provided an amount of qualified services and activities to low-income and underserved individuals with a value at least equal to the hospital's estimated property tax liability. The System has not recorded a liability for related property taxes based upon management's current determination of qualified services provided.

# Consolidating Balance Sheet Information June 30, 2017

(Dollars in thousands)

Assets	The University Chicago Medical Center	The University of of Chicago Medicine Care Network	UCMC Title Holding Corporation	Community Health and Hospital Division	Eliminations	Consolidated total
ASSETS	Center	Network	Corporation	DIVISION	Eliminations	totai
Current assets: Cash and cash equivalents Patient accounts receivable, net of estimated uncollectibles of \$140,878 Current portion of investments limited to use Current portion of malpractice self-insurance receivable Current portion of pledges receivable Due from affiliates Prepaids, inventory, and other current assets	\$ 13,74: 391,03 13,82 21,14 1,25: 13,78: 65,37:	1 322 1 — 1 — 6 — 0 — 9 806	5,453 — — — — — 1,683	18,225 40,747 6,787 — — — 19,060	(13,780) (1,007)	37,446 432,100 20,608 21,141 1,256 — 85,921
Total current assets	520,15	0 1,154	7,136	84,819	(14,787)	598,472
Investments, limited as to use, less current portion Property, plant, and equipment, net Pledges receivable, less current portion Malpractice self-insurance receivable, less current portion Other assets, net	903,71: 1,436,38: 2,36: 99,79: 353,83:	6 785 3 — 8 —	   	299,259 188,034 — — 8,147		1,202,972 1,625,205 2,363 99,798 38,654
Total assets	\$ 3,316,24	2 3,035	23,617	580,259	(355,689)	3,567,464
Liabilities and Net Assets					(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Current liabilities: Accounts payable and accrued expenses Current portion of long-term debt Current portion of other long-term liabilities Estimated third-party payor settlements Current portion of malpractice self-insurance liability Due to affiliates Due to the University of Chicago	\$ 165,99 13,86 1,20 160,67 21,14 - 28,72	8 — 5 — 8 — 1 — 13,192	408    411 	55,711 5,550 — 17,503 — —	(177) — (1,007) — — (13,603)	222,595 19,418 198 178,181 21,141 — 28,725
Total current liabilities	391,60	8 13,854	819	78,764	(14,787)	470,258
Workers' compensation self-insurance liability, less current portion Malpractice self insurance liability, less current portion Long-term debt, excluding current installments Interest rate swap liability Other long-term liabilities, less current portion	5,98 99,79 886,47 120,15 50,56	8 — 0 — 8 —	21,296 — 1,560	31,737 107,061 9,292 10,388		5,980 131,535 1,014,827 129,450 44,469
Total liabilities	1,554,57	5 13,854	23,675	237,242	(32,827)	1,796,519
Net assets (deficit): Unrestricted Temporarily restricted Permanently restricted	1,654,07 90,34 17,24	9	(58) — —	329,586 4,147 9,284	(309,740) (4,035) (9,087)	1,663,039 90,461 17,445
Total net assets	1,761,66	7 (10,819)	(58)	343,017	(322,862)	1,770,945
Total liabilities and net assets	\$ 3,316,24	2 3,035	23,617	580,259	(355,689)	3,567,464

See accompanying independent auditors' report.

## Consolidating Statement of Operations and Changes in Unrestricted Net Assets Information

For the year ended June 30, 2017

(Dollars in thousands)

	_	The University of Chicago Medical Center	The University of Chicago Medicine Care Network	UCMC Title Holding Corporation	Community Health and Hospital Division	Eliminations	Consolidated total
Revenue:							
Net patient service revenue Provision for doubtful accounts	\$	1,755,874 138,317	2,766		250,919 14,571		2,009,559 152,888
Net patient service revenue less provision for doubtful accounts		1,617,557	2,766	_	236,348	_	1,856,671
Other operating revenue and net assets released from restrictions	_	120,651	1,801	618	27,201	(1,481)	148,790
Total operating revenues	_	1,738,208	4,567	618	263,549	(1,481)	2,005,461
Operating Expenses: Salaries, wages, and benefits Supplies and other Physician services Insurance Interest Medicaid provider tax Depreciation and amortization	_	736,797 485,577 229,709 11,083 35,757 41,753 102,985	9,238 3,006 985 643 — — 349	81 — — 595 —	113,606 95,011 21,630 6,068 3,682 12,071 13,941	(31) (832) — (618) —	859,641 583,644 251,492 17,794 39,416 53,824 117,275
Total operating expenses	_	1,643,661	14,221	676	266,009	(1,481)	1,923,086
Operating revenue in excess of expenses	_	94,547	(9,654)	(58)	(2,460)		82,375
Nonoperating gains (losses), net: Investment income (loss) and unrestricted gifts, net Loss on extinguishment of debt Contribution of CHHD unrestricted net assets Change in fair value of nonhedged derivative instruments Derivative ineffectiveness on hedged derivative instruments Distributions and other, net	_	72,556 (27,028) 309,740 — 2,095			16,598 — 309,740 3,561 — 2,496	(309,740) — — — —	89,154 (27,028) 309,740 3,561 2,095 2,496
Net nonoperating gains (losses)	_	357,363			332,395	(309,740)	380,018
Revenue and gains in excess (deficient) of expenses and losses		451,910	(9,654)	(58)	329,935	(309,740)	462,393
Other changes in net assets:  Equity transfers to University of Chicago, net Change in accrued pension benefits other than net periodic benefit costs Effective portion of change in valuation of derivatives Other, net  Increase (decrease) in unrestricted assets	<u>-</u> \$	(71,750) 2,266 44,863 — 427,289	— — — ————————————————————————————————			(309,740)	(71,750) 2,266 44,863 (349) 437,423
	Ψ=	12.,200	(0,004)	(50)	020,000	(000,1.10)	,.25

See accompanying independent auditors' report.

# Consolidating Statement of Changes in Net Assets Information

For the year ended June 30, 2017

(Dollars in thousands)

		The University of Chicago Medical Center	The University of Chicago Medicine Care Network	UCMC Title Holding Corporation	Community Health and Hospital Division	Eliminations	Consolidated total
Unrestricted net assets:							
Revenue and gains in excess of expenses and losses	\$	451,910	(9,654)	(58)	329,935	(309,740)	462,393
Equity transfers to University of Chicago, net		(71,750)	_	_	_	_	(71,750)
Change in accrued pension benefits other than net periodic benefit cost		2,266	_	_	_	_	2,266
Effective portion of change in valuation of derivatives		44,863	_	_	_	_	44,863
Other, net	_				(349)		(349)
Increase (decrease) in unrestricted net assets	_	427,289	(9,654)	(58)	329,586	(309,740)	437,423
Temporarily restricted net assets:							
Contributions		2,687	_	_	750	_	3,437
Net assets released from restrictions used for operating purposes		(5,880)	_	_	(638)	_	(6,518)
Investment income		7,582	_	_	_	_	7,582
Contribution of CHHD temporarily restricted net assets	_	4,035			4,035	(4,035)	4,035
Decrease in temporarily restricted net assets		8,424	_	_	4,147	(4,035)	8,536
Permanently restricted net assets:							
Contribution of CHHD permanently restricted net assets		9,087	_	_	9,087	(9,087)	9,087
Contributions and other	_	49			197		246
Change in net assets		444,849	(9,654)	(58)	343,017	(322,862)	455,292
Net assets at beginning of year	_	1,316,818	(1,165)				1,315,653
Net assets at end of year	\$_	1,761,667	(10,819)	(58)	343,017	(322,862)	1,770,945

See accompanying independent auditors' report.